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ABSTRACT 
NOVEL AMINO ACID TRANSPORTER-TARGETED RADIOTRACERS FOR 
BREAST CANCER IMAGING 
 
Publication No._______ 
FanLin Kong, Ph.D. 
Supervisory Professor: David J. Yang, Ph.D. 
 
        Breast cancer is the most common malignancy among women in the world.  Its 
5-year survival rate ranges from 23.4% in patients with stage IV to 98% in stage I 
disease, highlighting the importance of early detection and diagnosis. 18F-2-Fluoro-
2-deoxy-glucose (18F-FDG), using positron emission tomography (PET), is the most 
common functional imaging tool for breast cancer diagnosis currently. Unfortunately, 
18F-FDG-PET has several limitations such as poorly differentiating tumor tissues 
from inflammatory and normal brain tissues. Therefore, 18F-labeled amino acid-
based radiotracers have been reported as an alternative, which is based on the fact 
that tumor cells uptake and consume more amino acids to sustain their uncontrolled 
growth. Among those radiotracers, 18F-labeled tyrosine and its derivatives have 
shown high tumor uptake and great ability to differentiate tumor tissue from 
inflammatory sites in brain tumors and squamous cell carcinoma. They enter the 
tumor cells via L-type amino acid transporters (LAT), which were reported to be 
highly expressed in many cancer cell lines and correlate positively with tumor 
vi 
 
growth. Nevertheless, the low radiosynthesis yield and demand of an on-site 
cyclotron limit the use of 18F-labeled tyrosine analogues. 
        In this study, four Technetium-99m (99mTc) labeled tyrosine/ AMT (α-methyl 
tyrosine)-based radiotracers were successfully synthesized and evaluated for their 
potentials in breast cancer imaging. In order to radiolabel tyrosine and AMT, the 
chelators N,N’-ethylene-di-L-cysteine (EC) and 1,4,8,11-tetra-azacyclotetradecane 
(N4 cyclam) were selected to coordinate 99mTc. These chelators have been reported 
to provide stable chelation ability with 99mTc. By using the chelator technology, the 
same target ligand could be labeled with different radioisotopes for various imaging 
modalities for tumor diagnosis, or for internal radionuclide therapy in future. 
        Based on the in vitro and in vivo evaluation using the rat mammary tumor 
models, 99mTc-EC-AMT is considered as the most suitable radiotracer for breast 
cancer imaging overall, however, 99mTc-EC-Tyrosine will be more preferred for 
differential diagnosis of tumor from inflammation. 
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CHAPTER 1   Introduction 
I. Breast cancer and its diagnosis 
a. Introduction 
        Breast cancer is the most common malignancy among women in the United 
States. In 2010, a total of 207,090 new cases of invasive breast cancer, along with 
54,010 new cases of non-invasive types, were expected to be diagnosed in women. 
Moreover, about 39,840 women were projected to die from this disease in the same 
year. According to the National Cancer Institute, the 5-year survival rate of breast 
cancer ranges from 23.4% in patients with stage IV disease to 98% in patients with 
stage I disease, highlighting the importance of early detection and diagnosis of 
breast cancer[1].  
        Molecular imaging serves as an essential tool in breast cancer diagnosis and 
staging, as well as provides a significant proportion of information for surgical 
management, radiation planning, chemotherapeutic assessment, and treatment 
response monitor of patients. In the present, positron emission tomography (PET), 
single photon emission computed tomography (SPECT), and their combinations 
with computed tomography (CT) or magnetic resonance imaging (MRI), are major 
functional molecular imaging modalities used in clinic. PET and SPECT radiotracers 
can target tumors based upon tumor-specific characteristics at molecular levels. 
The accumulating understanding of the breast cancer molecular biology has 
highlighted pivotal factors that are critical for breast cancer progression, which 
allows researchers to select suitable targets for developing tumor-specific 
radiotracers. For instance, given that sustained tumor growth demands elevated 
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glucose consumption for energy production in the lesion regions, PET radiotracer 
18F-labeled glucose analog 18F-2-fluoro-2-deoxy-glucose (18F-FDG) has commonly 
been used to visualize the glucose metabolism of breast cancer cells[2]. 18F-labeled 
16α-17β-fluoroestradiol is used to image estrogen receptors, which are highly 
overexpressed in a large proportion of breast tumor tissues[3]. Many other 
radiotracers have been designed to image cell proliferation, cell apoptosis, 
angiogenesis and hypoxia of breast tumors. Since breast cancer treatment has 
become more individualized in compliance with the distinct biological characteristics 
of tumors from each patient, the more target-specific molecular imaging radiotracers 
may hold the key to guide treatment selection and evaluate treatment response in 
the early stages. 
 
b.  Positron emission tomography (PET) and its radionuclides 
        Positron emission tomography (PET) is a 3-D nuclear medicine imaging 
technique, which is based on detecting the annihilation radiation emitted from a 
certain positron-emitting radionuclide[2]. When the radionuclide decays, the positron 
annihilates an electron nearby, thus creates two 511 keV photons emitted opposite 
to each other (180 degree). This process is called “coincidence event”, which can 
be observed by PET detectors arranged in an array of full or partial ring around the 
patient body axis. Data are then reconstructed using standard algorithm. By using 
this coincidence-detection method, the traditional collimator can be eliminated, and 
therefore the spatial resolution and sensitivity can be highly improved. 
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        Commonly used PET imaging radionuclides are listed in Table 1.1. In order to 
monitor a small bioactive molecule in vivo without altering its chemical structure, 
carbon-11 (11C) is often used as a label to substitute  the stable carbon atom 12C in 
that molecule. Given that 11C has a half-life of only 20 minutes which has less 
commercial interest, fluorine-18 (18F) with a half-life of 110 minutes has been used 
alternatively. In fact, 18F is currently the most frequently used/developed PET 
radionuclide. In addition to 11C- and 18F-labeled biomarkers, there are some other 
short half-lived radiotracers such as 15O-labeled water and 13N-labeled ammonia 
that measure blood flow in the patient body[4]. Moreover, copper-64 (64Cu) and 
zirconium-89 (89Zr), because of their long half-life (12.7 h and 78.4 h, respectively), 
have been increasingly recognized in the past decade for labeling nanoparticles or 
slowly localizing antibodies[5]. Other than those cyclotron-produced PET 
radionuclides mentioned above, generator-produced gallium-68 (68Ga) and 
rubidium-82 (82Rb) have also shown high potentials in PET imaging. The advantage 
of in-house generator produced radionuclides is that the generator itself serves as a 
top-of-the-bench source for short half-lived radionuclides in the places that are 
located far from the cyclotron facility. Besides, it is quite simple to access 
radionuclides from the generator, and less expensive compared to cyclotron-
produced radionuclides. 
 
c. PET-based radiotracers for breast cancer imaging in clinic 
        
18F-FDG, a glucose analogue, has become the most common and attractive 
radiotracer for PET. Both 18F-FDG and glucose are transported across the cell 
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membrane by glucose transporters. 18F-FDG is phosphorylated by hexokinase to 
18F-FDG-6-phosphate, whereas glucose is phosphorylated to glucose-6-phosphate. 
Unlike glucose-6-phosphate, 18F-FDG-6-phosphate cannot be further metabolized 
and therefore is trapped and accumulated steadily in tumor cells[2]. Hence, 18F-
FDG is able to provide high sensitivity for detecting, staging, and re-staging tumors 
by imaging high glucose metabolic rates in tumor cells. For breast cancer cells, 
increased glucose utilization is caused by the overexpression of the glucose 
transporters Glut-1 and Glut-3 and by increased hexokinase activity[6]. The rate-
limiting step in the uptake of 18F-FDG in breast cancer appears to be the 
phosphorylation process by hexokinase, particularly hexokinase I[6]. 
        Although 18F-FDG-PET generally has high sensitivity and specificity in 
detecting malignancies, whole-body 18F-FDG-PET is not quite suitable for primary 
breast cancer diagnosis, especially for low-grade tumors and tumors smaller than 1 
cm in diameter[7]. In addition, it is not appropriate to use 18F-FDG for breast cancer 
screening[8]. For locoregional staging of breast cancer, 18F-FDG-PET has shown 
high sensitivity in axillary staging of patients with late stage cancer, but it is not 
sensitive enough in detecting early-stage micrometastases and small tumor-
infiltrated axillary lymph nodes[9]. Nevertheless, 18F-FDG-PET appears to be 
suitable for distant (systemic) staging; it is also well suited for staging of locally 
advanced breast cancer, which usually has a large primary tumor (>5 cm in 
diameter) or advanced axillary disease without clinically apparent distant 
metastases[10]. Moreover, several studies have demonstrated that 18F-FDG-PET is 
superior to traditional bone scintigraphy in the detection of osteolytic and 
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intramedullary metastases but is inferior in the detection of primary osteoblastic 
lesions[11]. An increasing number of studies have used 18F-FDG-PET to evaluate 
treatment responses. Although 18F-FDG has not yet been recommended as a 
routine assessment agent, accumulated 18F-FDG uptake has been proven to be an 
accurate early predictor of poor response to therapy. In a study showing that high 
18F-FDG uptake was associated with a low blood flow or perfusion rate in tumors, 
the locally advanced breast cancer patients with high uptake were more likely to 
have poor response and early relapse[12].  
        Given its low specificity, many radiotracers have been developed as an 
alternative to18F-FDG. Table 1.2 summarizes the PET-based radiotracers that 
currently applied for breast cancer imaging, according to the categories of the 
tumor-specific targets to which they are aimed at. 
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Table 1.1. Radionuclides commonly used in PET imaging.  
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Table 1.2. PET-based radiotracers used to detect breast cancer in humans, by tumor-specific 
target. 
 
 
 
 
 
 
 
 
Target PET Radiotracer
Perfusion 15O-H2O
Glucose metabolism 18F-FDG
Hormone receptor
18F-FES
18F-fluorotamoxifen
21-[18F]fluoro-16α-ethyl-19-norprogesterone
16β-18F-fluoromoxestol
HER2 89Zr-trastuzumab
Cell proliferation 18F-FLT
Angiogenesis
18F-galacto-RGD
18F-AH111585
89Zr-bevacizumab
Amino acid transporters and protein 
synthesis
11C-methionine
11C-tyrosine
O-(2-[18F]fluoroethyl)-l-tyrosine
Epidermal growth factor receptor 11C-Iressa
Hypoxia
18F-fluoromisonidazole
18F-fluoroetanidazole
18F-fluoroazomycin-arabinoside
64Cu-diacetyl-bis-N4-methylthiosemicarbazone
Apoptosis 18F-annexin V
Membrane synthesis
11C-choline
18F-fluorocholine
Bone 18F-fluoride
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d. Planar scintigraphic imaging, single photon emission computed 
tomography (SPECT) and their radionuclides 
        Planar scintigraphic imaging uses one gamma camera to capture and 
determine gamma-ray emitting photons directly from the labeling radionuclide in a 
particular angle. The energy of the radionuclide for planar scintigraphic imaging is 
generally from 70 to 364 keV (Table 1.3). 
 
Table 1.3. Radionuclides commonly used in SPECT imaging. 
  
IT: isomeric transition 
EC: electron capture 
 
Radionuclide Decay Mode Half-life
Emitted Photon Energy 
[keV]
99mTc IT 6.01 h 140 (87.7%)
201Tl EC 73.0 h
71 (47%), 135 (3%), 167 
(10%)
123I EC 13.2 h 159 (83.3%)
131I Β- 8.02 d 364 (81.2%)
111In EC 67.4 h 171(90.3%), 245 (94%)
67Ga EC 78.3 h
93 (37%), 184 (20.4%), 300 
(16.6%)
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        Different from planar scintigraphic imaging, a typical single photon emission 
computed tomography (SPECT) system consists of one or more rotating gamma 
camera(s) to obtain multiple projection images from different views around the 
patient, and a computer algorithm for 3D image reconstruction. A collimator is 
required to collect the γ-ray photons that are emitted from the patient body only in a 
particular direction[13]. 
        Technetium-99m (99mTc, t1/2= 6.02 h) is the most common radionuclide for 
planar and SPECT imaging. It emits a 140 keV gamma ray in 89% abundance, 
which can be detected by NaI detectors. In addition, it is produced with in-house 
generator that contains the parent nuclide molybdenum-99 (99Mo), and does not 
require the cyclotron. Since the chemistry of diagnostic radionuclide 99mTc is very 
similar to that of the therapeutic radioisotope rhenium-188 (188Re), they could be 
labeled to the same ligand, which leads to the diagnostic/therapeutic matched 
pair[14]. 
        Although the resolution and sensitivity of SPECT is not as good as PET scan 
due to its physical nature, SPECT and SPECT/CT still play important and 
irreplaceable roles in nuclear imaging area. First of all, SPECT 
radiopharmaceuticals are comparatively easier and less costly to produce. In 
addition, given that most SPECT radionuclides have longer half-life than that of PET 
radionuclides, SPECT offers more possibility to broaden the observational time 
window that allows the doctors to monitor biological processes in vivo several hours 
or even days after radiopharmaceutical administration. Furthermore, only limited 
facilities around the world can afford complete armamentarium of PET instruments 
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and cyclotron for the local production of short-lived positron-emitters. Clinical data 
have shown that 15.9 million SPECT procedures were performed in 2007, while 
only 1.6 million of PET procedures were performed, in comparison[15]. 
 
e. Planar and SPECT-based radiotracers for breast cancer imaging in 
clinic 
        To date, the most common radiotracer used for SPECT and planar 
scintigraphic imaging such as scintimammography is 99mTc-methoxyisobutylisonitrile 
(99mTc-MIBI or 99mTc-sestamibi). Scintimammography has been increasingly used to 
assess the suspicious lesions of patients with a negative or indeterminate 
mammography in the clinic[16]. This small lipophilic cation was originally developed 
as a myocardial perfusion agent. The first report of its application in breast cancer 
detection was by Aktolun et al. in 1992[17]. The cellular uptake mechanisms of 
99mTc-sestamibi still remain unclear; however, its uptake is driven by a negative 
transmembrane potential and most of the radioactivity is found in the 
mitochondria[18]. 99mTc-sestamibi scintimammography shows higher sensitivity 
(85%) and specificity (87%) than the traditional mammography, and its sensitivity is 
independent of breast density[19]. In addition, 99mTc-sestamibi is a substrate of the 
transmembrane P-glycoprotein (Pgp), which is a member of the MDR/TAP 
subfamily that is involved in the multidrug resistance. Therefore, the uptake, 
clearance, and retention of 99mTc-sestamibi have been investigated as predictors of 
response to chemotherapy in human breast cancer[20]. In a study of 45 patients 
with primary breast cancer, Cayre et al concluded that a negative 99mTc-sestamibi 
11 
 
scintimammography predicted chemoresistance with a specificity of 100%. Besides, 
99mTc-sestamibi uptake was inversely correlated to the expression of multidrug 
resistance protein MDR1 (P<0.05) in invasive ductal carcinomas[21]. 
        Nevertheless, 99mTc-sestamibi scintimammography demonstrates relatively low 
sensitivity in detecting the nonpalpable lesions or tumors smaller than 1 cm[22]. 
Therefore, the high resolution small field-of-view breast-specific γ-imaging (BSGI) 
has been developed as an alternative. Similar to positron emission mammography 
(PEM), the single-head detector used in BSGI is mounted opposite to a 
compression plate, so the patient’s breast is compressed between detector and 
plate. According to a 6-year BSGI study performed by Hruska et al. at Mayo Clinic, 
the sensitivity of BSGI for tumors larger than 1 cm was 97%, while that for tumors 
smaller than 1 cm was 74%[23]. When comparing BSGI with PEM, although the 
average sensitivity of PEM (93%) is slightly higher than that of BSGI (89%), BSGI 
has a much higher negative predictive value (100%) than that of PEM (88%)[24]. 
Thus, both of the imaging modalities have great detection ability in existing studies, 
and there is no proven clinically significant advantage to either modality over the 
other so far. 
        Although not majorly used, several other radiotracers have been successfully 
developed as alternatives to 99mTc-sestamibi. Table 1.4 summarizes the 
radiotracers that currently applied to SPECT and planar scintigraphic imaging of 
breast cancer, categorized according to the tumor-specific targets to which they are 
aimed at. 
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Table 1.4. Planar and SPECT-based radiotracers used to detect breast cancer in humans, 
by tumor-specific target. 
 
 
 
 
 
 
 
 
 
 
 
Target SPECT or Gamma Imaging Radiotracer
Perfusion
Thallium-201
99mTc-sestamibi
99mTc-tetrofosmin
Glucose metabolism 99mTc-ethylenedicysteine-N-acetylglucosamine
Hormone receptor 123I-16α-estradiol
HER2 111In-trastuzumab
Angiogenesis
99mTc-NC100692
111In-bevacizumab
Amino acid transporters and 
protein synthesis
99mTc-methionine
L-3-123I-α-methyltyrosine
Apoptosis 99mTc-EC-annexin V
Somatostatin receptors 111In-diethylenetriamine pentaacetic acid-octreotide
Bone
99mTc-MDP
67Ga-citrate
13 
 
II. Amino acid transporter systems 
a. Introduction 
        Amino acids cross the cell membranes via various amino acid transporter 
systems based on their structures. The mammalian amino acid transporter systems 
can be classified as neutral, acidic or basic classes according to the substrates they 
transport. Each of the classes can be further divided into Na+-dependent and Na+-
independent transporter subclasses[25]. To date, more than 20 systems have been 
identified (Table 1.5), and the major systems that are present in all tissues are the 
Na+-dependent system A and ASC, as well as the Na+-independent system L[26-28]. 
Transport of an amino acid generally depends on the difference between its intra- 
and extra-cellular concentration, and is frequently associated with counter-transport 
of a second amino acid, whose gradient is controlled by one or more of the Na+-
dependent systems. 
        In tumor cells, amino acid transporters are generally upregulated to facilitate 
their increasing amino acid uptake[29, 30]. In addition to functioning as the basic 
building blocks of proteins, amino acids are also important sources of carbon and 
nitrogen in the synthesis of purine and pyrimidine nucleotides, amino sugars, and 
glutathione, which are the essential elements for rapid proliferation of tumor 
cells[31]. Therefore, the rate of amino acid uptake and transport, rather than the 
protein synthesis rate, is very crucial for tumor cells[32, 33].  
        The development of amino acid-based imaging probes has focused on 
radiolabeling the substrates of those amino acid transporter systems, especially for 
system L and/or A given that they are the two major transport systems in 
14 
 
mammalian cells. Here, we introduce systems A and L, their molecular biology and 
transport mechanisms. 
 
Table 1.5. Major amino acid transporter systems in mammalian. 
 
SLC: solute carrier family, a naming of transporter families by Human Gene 
Nomenclature Committee. 
 
 
 
 
 
 
Transporter System Substrate Transporter Family
Neutral
Na+-dependent
A Ala, Pro, N-methylamino acids ATA1-3 SLC38
ASC Ala, Ser, Thr, Cys, (Gln) ASCT1,2 SLC1
B0 Broad substrate selectivity
Β-system Β-Ala, Tau Taut SLC6
G Gly, Sar GLYT1,2 SLC6
N Gln, Asn, His SN1,2 SLC38
y+L Neutral and basic amino acids y+LAT1·4F2hc, y+LAT2·4F2hc SLC7
Na+-independent
asc Ala, Ser, Thr, Cys Asc-1·4F2hc, Asc-2·? SLC7
b0,+ Neutral and basic amino acids BAT1/b0,+AT·rBAT SLC7
L Large neutral amino acids LAT1-4·4F2hc, SLC7
T Aromatic amino acids TAT1 SLC16
Basic
Na+-dependent B0,+ Neutral and basic amino acids ATB0,+ SLC6
Na+-independent
b0,+ Neutral and basic amino acids BAT1/b0,+AT·rBAT SLC7
y+ Basic amino acids CAT1-4 SLC7
y+L Neutral and basic amino acids y+LAT1·4F2hc, y+LAT2·4F2hc SLC7
Acidic
Na+-dependent X-AG L-Glu, L-/D-Asp EAAC1, GLT-1, GLAST, EAAT4,5 SLC1
Na+-independent x-c Cys/Glu exchange xCT·4F2hc SLC7
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b. System A 
        System A is a Na+-dependent system that transports small neutral aliphatic 
amino acids. It can uniquely recognize and transport N-methylated amino acids, and 
thus, N-methyl aminoisobutyric acid (MeAIB) is used as a system A specific inhibitor 
to determine its substrates. It can also be characterized by tolerance of Li+ 
substitution for Na+, and by the property of trans-inhibition[34]. System A is pH 
sensitive and displays hormonal and adaptive regulation[35]. It has three subtypes: 
SNAT1 (the sodium-coupled neutral amino acid transporter 1), SNAT2, and SNAT4. 
Some of these subtypes are considered to be associated with cancers. For instance, 
Kondoh et al. demonstrated that SNAT1 mRNA expression in human hepatocellular 
carcinoma (HCC) cell lines was significantly higher than that of normal liver tissue. 
In addition, the expression of SNAT1 was significantly activated in HCC tissues as 
well as in premalignant cirrhotic livers from HCC patients[36]. 
 
c. System L 
        System L (L-type amino acid transporter system, or LAT) is a Na+-independent 
system for transporting large neutral amino acids such as branched or aromatic 
amino acids. It exchanges one amino acid from the extracellular compartment with 
one amino acid from the intracellular compartment (Fig. 1.1). LAT has broad 
substrate selectivity and four subtypes named LAT1-4, respectively. LAT1 and 
LAT2 have similar structures and their amino acid sequences show 50% identity in 
human. Both of them form heterodimeric complexes via a disulfide bond and 
comprise of a 12-transmembrane catalytic light chain and a type-II glycoprotein 
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heavy chain called 4F2hc (Fig. 1.1). Different from LAT1 and LAT2, the subtypes 
LAT3 and LAT 4 can function without 4F2hc; however, since both of them were 
identified recently, little is known about their molecular properties and functions. 
Among four subtypes, only LAT1 shows increased transport activity and plays an 
important role in proliferating cells such as placenta and tumor cells. LAT1 
upregulation has been observed in various cancer types as well as tumor cell lines, 
thus, is considered as a diagnostic and prognostic biomarker for cancers[37-40]. 
LAT1 transports not only amino acids, but also some hormones such as thyroxine 
and triiodothyronine, as well as other drugs such as L-DOPA for Parkinson’s 
disease and melphalan for cancer treatment[41]. BCH (2-amino-endo-
bicycloheptane-2-carboxylic acid), a specific inhibitor of LAT, is often used to 
determine whether a certain compound like amino acid-based radiotracer is LAT 
substrate[42]. 
 
 Figure 1.1. Predicted structure of L
mechanism. 
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III. Tyrosine-based radiotracers for tumor imaging 
a. 11C-labled tyrosine analogue 
        Theoretically, all amino acids can be labeled with 11C since all of them contain 
at least two carbons (the carboxyl carbon and the α-carbon) that can serve as 
labeling sites. Although 11C is adequate for amino acid-based PET imaging, which 
typically has peak tumor uptake 15-20 min after i.v. injection, the 20 min half-life of 
11C restricts its use only to the institutions that have an onsite cyclotron, and thus, 
makes it clinically impractical[43]. 
        L-[1-11C]-tyrosine (11C-Tyr) is a reliable amino acid-based PET probe for tumor 
detection and quantification in multiple types of malignancies, including brain[44], 
breast[45], head and neck cancers[46], and soft tissue sarcomas[47]. Since 11C-Tyr 
is largely incorporated into proteins, it has been used as an appropriate probe for 
protein synthesis rate quantification. Same as its precursor tyrosine, 11C-Tyr has 
been proven to enter the tumor cells predominantly via amino acid transport system 
L.  
        There are mainly three approaches to synthesize 11C-Tyr: via the Bücherer-
Strecker reaction[48], an enzymatic route[49], and the robotic synthesis using 
isocyanide method[50]. 11C-Tyr can be obtained within 50-60 min in a high purity 
(>98%) through each method, however, the overall radiochemical yield by robotic 
synthesis was relatively lower than the other two methods (10% vs. 40-60%). 
Regardless of its low synthetic yield, the robotic synthesis is preferable because it is 
a convenient procedure for routine 11C-Tyr production and can avoid high dose 
radiation exposure and contamination. 
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        To date, many studies have been conducted to compare the imaging potentials 
between 11C-Tyr and 18F-FDG. 11C-Tyr appears to be better than 18F-FDG for breast 
cancer imaging because of its lower uptake in fibrocystic disease[45]. 11C-Tyr-PET 
showed higher specificity (95% vs. 88%), accuracy (95% vs. 88%), and positive 
predictive value (63% vs. 48%) than those of 18F-FDG-PET in detecting cervical 
lymph nodes of 11 patients with squamous cell carcinoma of the oral cavity[51]. 
Furthermore, prolactinomas could be clearly visualized by 11C-Tyr-PET, but not 18F-
FDG-PET[52]. Kole et al. compared 18F-FDG and 11C-Tyr imaging potentials in 
patients with soft-tissue tumors before and after chemotherapy and found out that 
although 18F-FDG had a better indication of tumor grade, 11C-Tyr was more 
accurate in predicting proliferation and mitotic rate of the tumor lesions, especially 
after treatment[53]. In another study, Boer et al. have demonstrated a significant 
positive relationship between high 11C-Tyr uptake and poor survival rate of patients 
with laryngeal carcinoma under radiotherapy[54]. However, 11C-Tyr seems not 
suitable for visualizing the tumors with a low proliferation rate such as testicular 
nonseminoma germ-cell tumor[55]. 
 
b. 123I-labeled tyrosine analogue 
        The SPECT radionuclide 123I has a long half-life of 12.3 hr, which allows the 
imaging of slower biological processes taking place over the course of 1-2 days. 
        3-[123I]iodo-α-methyl-L-tyrosine (123I-IMT) is a useful SPECT imaging probe for 
diagnostic evaluation and therapy planning to patients with brain tumors[56]. It can 
be synthesized by direct electrophilic iodination of α-methyl-L-tyrosine (AMT) in the 
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presence of an oxidizing agent such as Chloramine-T[57] and Iodogen[58]. The 
average radiochemical yield ranges from 60-80%.  
         
123I-IMT is dominantly transported by amino acid transport system L and not 
incorporated into proteins. It is eliminated via renal clearance, and the highest 
absorbed doses are observed in bladder, colon, and kidneys[59]. Although it was 
not ideal to determine prognosis and grade of gliomas, 123I-IMT-SPECT still 
succeeds to image the extent of cerabral gliomas as well as their recurrences, and 
to differentiate recurrences from radionecrosis[60-62]. For extracranial tumors, 123I-
IMT-SPECT has been used to evaluate non-small cell lung cancer[63], head and 
neck cancer[64], melanoma[65], and soft tissue sarcomas[66]; however, most of 
those clinical results were similar or even inferior to those from 18F-FDG-PET. 
Plotkin et al. demonstrated that the positive predictive value in the diagnosis of 
relapsed head and neck cancer could be improved by integrating  low-dose CT with 
123I-IMT-SPECT[67, 68]. Therefore, 123I-IMT applied with combined SPECT/CT 
imaging is recommended for the future clinical studies.  
        Other than 123I-IMT, iodine-125-labeled 3-[125I]iodo-α-methyl-L-tyrosine was 
also synthesized and evaluated in vitro and in vivo[69-71], however, no clinical 
study has been reported so far.  
 
c. 18F-labeled tyrosine analogues 
        Compared to 11C with a 20 min short half-life, 18F has a 109.8 min half-life and 
thus can be remotely distributed to the institutions without an onsite cyclotron. An 
increasing number of 18F-labeled tyrosine analogues have been developed, and 
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their transport mechanisms as well as potentials to image tumors have been 
intensively under investigation. The three major 18F-labeled tyrosine-based 
radiotracers are discussed here. 
 
1. L-2-[18F]fluorotyrosine (18F-Tyr) 
        L-2-[18F]fluorotyrosine (18F-Tyr) was first evaluated as a PET tracer of cerebral 
protein synthesis by Coenen et al in 1989[72]. The initial synthetic route is shown in 
Fig. 1. 2a . Briefly, [18F]acetylhypofluorite is used for electrophilic radiofluorination of 
O-acetyltyrosine in CF3COOH as solvent at 00C. After base-catalyzed hydrolysis of 
the acetyl moiety, the final product 18F-Tyr then can be isolated from the isomeric 
mixture via reverse phase HPLC with a specific activity of 10-20 GBq/mmol in a 17% 
yield[72]. Recently, Melean et al reported a new 3-step nucleophilic synthesis 
procedure starting with [18F]fluoride, and the total synthetic yield of 18F-Tyr was 
optimized up to 49% (Fig. 1. 2b). 
 
    
 
Fig. 1. 2a. The initial synthetic scheme of L-[2-18F]Fluorotyrosine.  
 
 
Fig. 1. 2b. The optimized synthetic scheme of L-[2-18F]Fluorotyrosine.  
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     18F-Tyr has been successfully used for detecting brain tumors[73]; however, it 
appears to be less sensitive for staging non-small cell lung cancer and lymphomas 
compared to 18F-FDG[74]. 
 
2. L-[3-18F]-α-methyl tyrosine (18F-FMT) 
        Due to its lower physioligical uptake in cortex than that of 18F-FDG, L-[3-18F]-α-
methyl tyrosine (18F-FMT) was initially studied as a brain tumor imaging agent for 
PET by Inoue et al[75]. It was developed based on the same concept of its 
iodinated SPECT counterpart 123I-IMT, and hence, the metabolic behavior of 18F-
FMT appears to be similar as that of 123I-IMT. 18F-FMT accumulates in the tumor 
cells solely via amino acid transporter system L, especially the LAT1 subtype, and 
shows no incorporation into proteins[76].  
        18F-FMT can be successfully synthesized following a simple and quick 
procedure designed by Tomiyoshi et al[77]. Briefly, [18F]F2 gas is converted to 18F-
labelled acetylhypofluorite, which is then bubbled into the solution containing 10 mg 
of L-α-methyltyrosine in 0.5 mL of trifluoroacetic acid (00C). The radiochemical yield 
and purity of 18F-FMT were 20.3±5.1% and 99.4±0.3%, respectively. 
        In addition to its application in brain tumors, 18F-FMT has also been 
extensively investigated for its potential in detecting musculoskeletal tumor[78], 
maxillofacial tumor[79], oral squamous cell carcinoma[80], and non-small cell lung 
cancer[81-83]. In a study of 75 patients with musculoskeletal tumor, Watanabe et al 
concluded that although 18F-FDG may be better for tumor grading, 18F-FMT had 
higher specificity in differentiating between benign and malignant tumors[78]. In 
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another study of patients with untreated malignant maxillofacial tumor, 18F-FMT-
PET had better contrast of tumor visualization to the surrounding normal structures 
than 18F-FDG-PET in 27 out of 36 patients[79]. Furthermore, Kaira et al 
demontrated that 18F-FMT had no false-positives in detecting primary non-small cell 
lung cancer and lymph node metastasis. In addition, they showed that LAT1 
expression was a strong prognostic factor in non-small cell lung cancer patients, 
and 18F-FMT uptake in the tumor lesions was positively correlated with LAT1 
expression (ρ=0.890)[81, 82]. 
 
3. O-(2-18F-Fluoroethyl)-L-Tyrosine (18F-FET) 
        O-(2-18F-fluoroethyl)-L-Tyrosine (18F-FET) is a promising PET probe for 
diagnosis of brain tumors and extracranial squamous cell carcinomas[84]. Several 
strategies for 18F-FET synthesis have been reported. 18F-FET was initially prepared 
via a 2-step procedure, alkylation of the L-tyrosine di-potassium salt with 
[18F]fluoroethyltosylate (Fig. 1.3a)[85]. By following this procedure, 18F-FET could be 
obtained in about 50 min with an overall yield of 40% and the specific activity 
was >200 GBq/µmol. However, this procedure is not suitable for automation 
because the separation and purification steps require HPLC. Later, the synthesis of 
18F-FET was improved by the implementation of direct nucleophilic radiofluorination 
on protected alkyl tyrosine derivative, O-(2-tosyloxyethyl)-N-trityl-L-tyrosine tert.-
butylester (Fig. 1.3b). Although the radiochemical yield was much higher  (60%), it 
took about 80 min for the entire process to complete due to the neccessity of HPLC 
purification to remove the solvent and an aggressive TFA[86]. So far, the best 
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synthesis route of 18F-FET, which suits perfectly for automation modules, was 
reported by Krasikova et al in 2008[87]. It is a novel type of chiral enantiomercially 
pure labeling precursor based on NiII complex of a Schiff’s base of (S)-[N-2-(N’-
benzylprolyl)amino]benzophenone (BPB) with alkylated (S)-tyrosine, Ni-(S)-BPB-
(S)-Tyr-OCH2CH2OTs (Fig. 1.3c). The overall synthesis time was 55 min, and the 
radiochemical yield was 40-45%.   
        18F-FET is primarily transported by the Na+-independent amino acid transport 
system L, as well as the Na+-dependent amino acid transporter system B0,+ and B0. 
18F-FET is not incorporated into proteins[85].  
        For the clinical studies, 18F-FET has always been compared to the same 
amino acid-based radiotracer 11C-MET, or the gold standard of tumor imaging tracer 
18F-FDG. In a study of 16 patients with suspected primary or recurrent intracerebral 
tumors, 18F-FET-PET showed similar uptake and image contrast as those of 11C-
MET[88]. However, 18F-FET accumulates to a significantly greater extent in tumor 
cells than in inflammatory cells when compared to 18F-FDG or 11C-MET, and 
therefore, shows better differentiation between tumor and inflammatory lesions in 
vivo[89, 90]. In fact, Popperl et al revealed that 18F-FET-PET could reliably 
distinguish post-therapeutic benign lesions, which may have a certain extent of 
inflammation, from tumor recurrence after initial treatment of both low- and high- 
grade gliomas[91]. In addition, Plotkin et al concluded that 18F-FET-PET was 
superior to 18F-FDG-PET for biopsy planning in patients with non-contrast-
enhancing brain tumors diagnosed by MRI[92]. Although 18F-FET-PET itself already 
has high sensitivity (88-100%), specificity (88-92.9%), and positive predictive value 
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(84%) in glioma diagnosis[93-95], it is highly recommended to combine its 
application with MRI and MR spectroscopy[94]. Furthermore, 18F-FET appears to be 
suitable for the prognosis of glioma. Hutterer et al suggested that 18F-FET-PET 
might predict the failure of antiangiogenic treatment such as bevacizumab-
irinotecan in patients with recurrent high-grade glioma[96]. Besides, Floeth et al 
suggested that the baseline amino acid uptake on 18F-FET-PET and a diffuse 
versus circumscribed tumor pattern on MRI were strong predictors for the outcomes 
of treatments to patients with low-grade glioma[97]. When the dynamic 18F-FET-
PET imaging in patients with glioblastoma is quantified, the ratio of standard uptake 
value (SUV) to background may provide a more valuable predictive measurement of 
the clinical outcome rather than the conventional SUV or distribution volume[98]. 
        Unlike 18F-FMT, 18F-FET is more dedicated in brain tumor imaging. Several 
studies were performed on the patients with head and neck cancer, however, 18F-
FET imaging on those patients were not sensitive and specific enough to replace 
the 18F-FDG[99-101].  
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Fig. 1.3a. The initial synthetic scheme of O-2-[18F]fluoroethyl-L-tyrosine.  
 
 
Fig. 1.3b. The optimized synthetic scheme of O-2-[18F]fluoroethyl-L-tyrosine.  
 
 
Fig. 1.3c. The best synthetic scheme of O-2-[18F]fluoroethyl-L-tyrosine.  
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IV. Technetium-99m and its coordination with chelators 
        Technetium-99m ( 99mTc) -based radiopharmaceuticals have been developed 
for cancer diagnostics since the 1960’s[102]. 99mTc is an ideal radioisotope for 
diagnostic imaging studies, because of its physical characteristics. It emits a 140 
keV γ-ray in 89% abundance, which can be detected by NaI detectors with low 
energy high-resolution collimator in the standard gamma camera[103]. 99mTc has a 
half-life of 6.02 h, which is ideal for preparation of radiolabeled small ligands and 
proteins[14]. It can be produced with in-house generator that contains the parent 
nuclide molybdenum-99 (99Mo), and does not require a cyclotron[104]. In addition, 
technetium (Tc) is a second-row transition element in Group 7, right above rhenium 
(Re), which has the radioisotope rhenium-188 (188Re) for cancer therapeutic 
applications[103]. Therefore, Tc chemistry is very similar to that of Re, which forms 
a diagnostic/therapeutic matched pair. Furthermore, due to their identical 
coordination parameters with the same ligands, a Re complex is a good structural 
model for the corresponding 99mTc complex because Re does not have any 
radioactivity and the structure of its complex can be confirmed safely [103]. 
        N,N’-ethylene-di-L-cysteine (EC) has been used as a strong chelator to trap 
the radioisotopes such as 99mTc, 188Re, and gallium-68 (68Ga)[105-107].  99mTc 
labeled EC is used as a renal imaging agent, which shows identical imaging 
properties but higher plasma clearance than the most widely used clinical agent, 
99mTc-mercaptoacetyltriglycine (99mTc-MAG3)[107]. The rhenium complex of EC, 
Re-EC, has also been synthesized and the structure has been determined by 
single-crystal X-ray diffraction[107].        
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        On the other hand, 1,4,8,11-tetra-azacyclotetradecane (N4 cyclam), one of the 
most common macrocyclic tetraamines, has also been reported as an efficient  
chelator for 99mTc labeling[108, 109]. The 99mTc-N4 complex is hexacoordinate with 
a trans-Tc (V)-dioxo core and positively charged (+1).  
        By taking the advantage of chelators such as EC and N4 cyclam, we can label 
the tumor-target ligands with several different radioisotopes for SPECT or PET 
imaging, and for the radiotherapeutic purposes, respectively. 
 
V. Scope of the dissertation 
        In this dissertation, four 99mTc-labeled tyrosine derivatives have been 
synthesized and evaluated in vitro and in vivo for their imaging potentials in a breast 
cancer model (Fig. 1.4).  We chose tyrosine and its derivative α-methyl tyrosine 
(AMT) as the target ligands based on the preexisting promising clinical outcomes of 
application of their 18F-labeled analogues. In addition, the structures of tyrosine and 
AMT can be readily modified without changing their favorable biological 
characteristics. In order to radiolabel tyrosine and AMT with 99mTc, we used 
chelators EC and N4 cyclam, which have been reported to have the ability to stably 
chelate with 99mTc[108, 110]. By taking advantage of the chelator technology, we 
can label the same target ligand with different radioisotopes for various imaging 
modalities in tumor diagnosis, or label the ligand with the therapeutic radioisotopes 
for cancer treatment in future. 
        Our hypothesis is that 99mTc-labeled tyrosine/AMT-based radiotracers provide 
great potential in breast cancer imaging by accumulating in tumor cells via the L-
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type amino acid transporter system (LAT), and they can well differentiate tumor 
from inflammation. To test this hypothesis in each radiotracer, three specific aims 
are addressed: 
Specific Aim 1. Synthesize tyrosine/AMT-based precursor and label it with 99mTc. 
Specific Aim 2. Investigate the uptake kinetics and transport mechanisms of 99mTc-
labeled tyrosine/AMT-based radiotracer in rat mammary tumor cell line 13762. 
Specific Aim 3. Assess the kinetics of 99mTc-labeled tyrosine/AMT-based 
radiotracer accumulation in tumor and inflammation tissues in a rat mammary tumor 
model.  
        Chapter 1 has served as an introduction to the whole project. In Chapter 2-5, 
each chapter describes the synthesis and biological evaluation of one compound. 
Chapter 6 constitutes an overview of the project and compares four compounds 
based on the three specific aims that were presumed to be addressed. 
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Figure 1.4. Proposed structures of four tyrosine-based precursors. 
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CHAPTER 2   Development of 99mTc-EC-Tyrosine for breast cancer 
imaging    
I. Introduction 
        Currently 18F-FDG is the most common radiotracer for PET in tumor detection 
and staging. However, 18F-FDG has several limitations that give rise to false 
positive/negative diagnosis. For instance, 18F-FDG has poor contrast in brain tumor 
due to the high glucose uptake in both normal and neoplastic brain tissues[111], 
and it has poor differentiation of tumor from inflammatory tissue because of the high 
18F-FDG uptake in granulocytes and macrophages[112, 113]. Therefore, 
radiolabeled amino acids have been developed as an alternative to 18F-FDG. Their 
use in tumor detection is based on an increased uptake of amino acids in tumor 
cells, which is assumed to reflect an enhanced amino acid transporter, metabolism, 
and protein synthesis[114]. In contrast to glucose analog 18F-FDG, the uptake of 
amino acids in macrophages and other inflammatory cells is lower, so amino acid-
based radiotracers are considered to be more specific than 18F-FDG[84]. Among all 
radiolabeled amino acids, aromatic ones such as tyrosine and its derivatives are 
more suitable given their easier chemistry alterations and favorable biological 
characterizations. To date, tyrosine and its α-methyl substituted analog AMT have 
been successfully labeled with 11C[115, 116], 18F[75, 81] and 124/125I[65] for PET 
imaging, as well as 123/131I[56] for SPECT imaging, respectively. Most of those 
radiolabeled tyrosine analogs show promising preclinical and clinical results in 
tumor imaging, particularly in brain tumor staging. In addition, they have been 
proven to accumulate into the tumor cells predominantly via LAT, which is the only 
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system that can transport large neutral amino acids with aromatic rings[38, 41]. LAT, 
especially its subtype LAT1, is an ideal target for tumor imaging because it is up-
regulated and highly expressed in many cancer cell lines and positively correlated 
with tumor growth[117, 118]. 
        Although the existing radiolabeled tyrosine and its derivatives have shown very 
promising clinical outcomes, most of them require an on-site cyclotron to produce 
the radioisotope, which is inconvenient and expensive. Besides, the half-life of the 
radioisotopes are either too short (i.e. 20 min for 11C) or too long (i.e. 57.4 days for 
125I). Furthermore, iodine-labeled compounds are not stable in vivo because of 
deiodination. So far, 18F has the most appropriate half-life (110 min), however, the 
radiosynthesis yield of 18F-labeled compounds appear to be relatively low because 
of its electrophillic fluorination step. Therefore, it is desirable to develop a 
radiotracer with simpler chemistry and affordable isotope, which can be used 
clinically in most major medical facilities. 99mTc has favorable physical 
characteristics for diagnostic imaging studies. It emits a 140 keV gamma ray in 89% 
abundance, which is commonly used by gamma camera and SPECT. Its relatively 
long half-life (6.02 h) can provide serial images which overcomes the drawback of 
Fluorine-18 [103]. The chelator EC is known to chelate 99mTc stably owing to the 
efficient binding of the oxotechnetium group to two thiols and two amine nitrogen 
atoms of EC[107]. By taking the advantage of using the chelator EC, we could label 
several other radioisotopes such as Gallium-68, Indium-111, or Rhenium-188 with 
the same ligand for diagnostic and therapeutic applications in future[105, 107]. Here, 
we report the synthesis of 99mTc-labeled tyrosine using EC as a chelator, and its 
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potential in breast tumor imaging is evaluated.  
 
II. Materials and methods 
Chemicals and Analysis 
        EC was purchased from Taiwan Hopax Chems, Mfg, Co., Ltd. (Kaohsiung, 
Taiwan). All other chemicals of analytical grades and solvents of HPLC grade were 
obtained from Sigma-Aldrich (St. Louis, MO). Nuclear magnetic resonance (NMR) 
was performed on Bruker 300MHz Spectrometer (Bruker BioSpin Corporation, 
Billerica, MA), and mass spectra were performed on Waters Q-TOF Ultima Mass 
Spectrometer (Milford, MA) at the chemistry core facility at the University of Texas 
MD Anderson Cancer Center (UTMDACC; Houston, TX). Chemical shifts were 
reported in δ (ppm) and J values in Hertz. Sodium pertechnetate (Na99mTcO4) was 
obtained from 99Mo/99mTc generator by Mallinckrodt (Hazelwood, MO). 18F-FDG was 
obtained from Department of Nuclear Medicine at UTMDACC. 
 
Synthesis of Precursor EC-Tyrosine  
a) N-t-Butoxycarbonyl-O-[3-Br-propyl]-L-tyrosine methyl ester (compound 
1).  
        N-t-Butoxycarbonyl-L-tyrosine methyl ester (25 g; 0.085 mol) was dissolved in 
acetone (300 mL). 1,3-dibromopropane (17.3 mL; 0.169 mol) and K2CO3 (58 g; 
0.420 mol) were added under nitrogen. The reaction mixture was refluxed at 80 oC 
overnight. After cooling and filtration, the solvent was removed under reduced 
pressure, and the residue was dissolved in chloroform. The residue was washed 
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with water and dried with anhydrous MgSO4. The product was purified by column 
chromatography using a silica gel column, eluted with hexane/ethyl acetate (2:1 v/v) 
to yield 33.3 g (94.6%). Ms(m/z): 440.09 [M+Na]+. 
 
b) N-t-Butoxycarbonyl-O-[3-(N-Ethylenedicysteine) propyl]-L- tyrosine 
(compound 2).  
        EC (4.7 g, 17.6 mmol) was dissolved in water (50 mL), and the pH was 
adjusted to pH 8-9 by NaOH (1N). Compound 1 (5.1 g, 12.3 mmol) in ethanol (100 
mL) was added to the above solution, followed by adding K2CO3 (12.13 g, 88 mmol). 
Reaction mixture was then heated at 80 oC overnight. After cooling, the solvent was 
removed under reduced pressure, and the residue was dissolved in chloroform (50 
mL). The residue was washed with water, dried with anhydrous MgSO4, and 
evaporated to dryness. Without further purification, the compound 2 was used for 
following steps. 
 
c) O-[3-(N-Ethylenedicysteine) propyl]-L- tyrosine (EC-Tyrosine) 
(compound 3). 
        The crude product of compound 2 (2.5 g, 4.24 mmol) was dissolved in ethanol 
(50 mL). Hydrobromic acid (48%, 4.5 mL) was added dropwisely to the solution over 
30-min period at room temperature with stirring. After filtration, the white solid was 
washed with ethanol and recrystallized in water to yield 1.73 g.   
 
Radiolabeling of EC-Tyrosine and EC with 99mTc 
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        EC-Tyrosine (1 mg) was dissolved in 0.2 mL sterile water, followed by adding 
tin (II) chloride (0.1 mL, 1 mg/mL). For EC labeling, EC (0.5 mg) was dissolved in 
0.2mL sterile water by adding 10 uL of 1N NaOH (pH=9). Required amount of 
Na99mTcO4 was added to EC or EC-Tyrosine solution (pH 7.4). Radiochemical purity 
was determined by radio-HPLC (High performance liquid chromatography; Waters, 
Milford, MA), eluted with acetonitrile: water (7:3) using a flow rate of 0.5 mL/min. 
 
Determination of the Partition Coefficient 
        To determine the lipophilicity, 20 µL of 99mTc-EC-Tyrosine was added into an 
equal volume mixture of 1-octanol and sterile water in a centrifuge tube. The 
mixture was vortexed at room temperature for 1 min and then centrifuged at 5000 
rpm for 5 min. From each phase, 0.1 mL of the aliquot was taken out and the 
radioactivity was measured by gamma counter (Cobra Quantum; Packard, MN). 
The measurement was repeated for three times, and care was taken to avoid cross 
contamination between the phases. The partition coefficient value, expressed as 
logP, was calculated using the following equation: 
LogP = Log (radioactivity in 1-octanol layer / radioactivity in sterile water layer) 
 
 In Vitro Cellular Uptake Studies 
        Rat breast tumor cell line 13762 (American Type Culture Collection, Rockville, 
MD) was selected and the same cell line was used to create the animal model for in 
vivo evaluation. Cells were maintained in Dulbecco’s modified Eagle’s medium and 
nutrient mixture F-12 Ham (DMEM/F12; GIBCO, Grand Island, NY) at 37 oC in a 
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humidified atmosphere containing 5% CO2. Cells were plated onto 6-well tissue 
culture plates (2x105 cells/well) and incubated with 99mTc-EC-Tyrosine (0.05 mg/well, 
8 uCi/well), the negative control 99mTc-EC (0.025 mg/well, 8 uCi/well), or 18F-FDG (8 
uCi/well) for 0-4 h. After incubation, cells were washed with ice-cold PBS twice and 
detached by treating them with 0.5 mL of trypsin for 5 min. Cells were then collected 
and the radioactivity was measured with gamma counter. Data were expressed in 
mean ±S.D. percent of cellular uptake (%Uptake) in triplicate. 
 
In Vitro Competitive Inhibition Study  
        To investigate the transport mechanisms of 99mTc-EC-Tyrosine, the competitive 
inhibition study using L-tyrosine was conducted. Rat breast tumor cells were co-
incubated with 99mTc-EC-Tyrosine (8 µg/well, 8 µCi/well) and L-tyrosine for up to 1 h. 
A set of concentrations of L-tyrosine (10x, 50x, and 100x of the EC-Tyrosine 
concentration) were used. After incubation, cells were washed with ice-cold PBS 
twice and detached by treating them with 0.5 mL of trypsin for 5 min. Cells were 
then collected and the radioactivity was measured by gamma counter. Data were 
expressed in mean ±S.D. percent of cellular uptake (%Uptake) in triplicate. 
 
Blood Clearance 
        All animal work was carried out in the Small Animal Imaging Facility (SAIF) at 
UTMDACC under a protocol approved by Institutional Animal Care and Use 
Committee (IACUC). For blood clearance analysis, three normal female Fischer 344 
rats (150±25 g) (Harlan Sprague-Dawley, Indianapolis, IN) were intravenously 
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injected with 30 µCi 99mTc-EC-Tyrosine. Blood samples were drawn through lateral 
tail vein at several time-points from 5 min to 24 h (n=3/rat) by microliter pipettes (10 
µL). The blood samples were measured for radioactivity by gamma counter, and 
then were calculated as percentage of the injected dose per gram of blood (%ID/g). 
 
In Vivo Tissue Distribution Study of 99mTc-EC-Tyrosine  
        Tissue distribution studies of 99mTc-EC-Tyrosine (study I, n=9) and 18F-FDG 
(study II, n=9) were conducted by using normal female Fischer 344 rats (150±25 g, 
n=18). For each compound, the rats were divided into three groups for three time 
intervals (0.5, 2, 4 h for 99mTc-EC-Tyrosine; 0.5, 1, 2 h for 18F-FDG; n=3/time point). 
The injection activity was 25±0.5 µCi/rat intravenously. At each time interval, the 
rats were sacrificed, and the selected tissues were excised, weighed and measured 
for radioactivity by gamma counter. Each sample was calculated as percentage of 
the injected dose per gram of tissue wet weight (%ID/g). Counts from a diluted 
sample of the original injection were used as reference.  
  
Planar Scintigraphic Imaging Study 
        Female Fischer 344 rats were inoculated subcutaneously with 0.1 mL of breast 
tumor cells 13762 suspension in PBS (105 cells/rat) into the right legs. Planar 
scintigraphic imaging of 99mTc-EC-Tyrosine was performed 12-14 days after 
inoculation when tumors reached approximately 1 cm in diameter. Planar 
scintigraphic images were obtained using M-CAM (Siemens Medical Solutions, 
Hoffman Estates, IL) equipped with a Low Energy High Resolution collimator. 
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Anesthetized breast tumor-bearing rats were injected intravenously with 99mTc-EC-
Tyrosine (0.3 mg/rat, 300 µCi/rat; n=3). The images were acquired up to 4 h post-
administration of tracers. Computer outlined regions of interest (ROIs in counts per 
pixel) between tumor and muscle were used to calculate tumor/muscle (T/M) ratios. 
Percentage of the injected dose (%ID) of tumor was also calculated from the 
reference standard, which was 1/10 of the original injection activity. 
 
In Vivo Uptake Blocking Study 
        To ascertain whether 99mTc-EC-Tyrosine uptake is mediated specifically by 
LAT, in vivo blocking studies using the unlabeled L-Tyrosine as the competitive 
inhibitor was conducted. The same animal model used in the planar scintigraphic 
imaging study was employed. Unlabeled L-Tyrosine (50 mg/kg) dissolved in 0.3 mL 
saline (pH adjusted to 2-3) was administered intravenously to mammary tumor–
bearing rats 1 h prior to 99mTc-EC-Tyrosine injection. Planar scintigraphic images 
were acquired up to 4 h, and ROIs of liver, kidneys, tumor, and muscle were used to 
calculate the ratios of liver/muscle, kidney/muscle, and tumor/muscle, respectively. 
In addition, %IDs of liver, kidneys, tumor, and muscle were calculated from the 
reference standard, which was 1/10 of the original injection activity. The results 
were compared with those from the rats injected with 99mTc-EC-Tyrosine alone 
(control). 
 
Tumor and Inflammation Uptake Comparison In Vivo 
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        To investigate whether 99mTc-EC-Tyrosine can differentiate tumor from the 
inflammatory tissue, a rat model bearing both mammary tumor and turpentine oil-
induced inflammation was created. 13762 rat mammary tumor cells (105 cells/0.1 
mL PBS/rat) were inoculated into the right calf muscles of the female Fischer 344 
rats. After the tumors reached to 1 cm in diameter, turpentine oil (0.1 mL/rat) was 
injected into the left calf muscles of the rats to induce inflammation. The 
anesthetized rats (n=3) were injected intravenously with 99mTc-EC-Tyrosine 24 h 
after the turpentine injection. Planar scintigraphic images were acquired up to 4 h, 
and ROIs of tumor, inflammation, and muscle were used to calculate the tumor-to-
muscle ratios (T/Ms), inflammation-to-muscle ratios (I/Ms), and tumor-to-
inflammation ratios (T/Is), respectively. Same animal model was used to evaluate 
18F-FDG. Micro-PET imaging of 18F-FDG was performed using R4 micro-PET 
scanner (Concorde Microsystems, TN). The rats were injected intravenously with 
18F-FDG (500 uCi/rat, n=3), and dynamic PET scans were obtained for 90 min with 
a spatial resolution of 2.2 mm. PET images were reconstructed by using the 
ordered subset expectation maximization (OSEM) algorithm. T/Ms, I/Ms and T/Is 
ratios were calculated based on the regional radioactivity concentrations (µCi/cm3) 
that were estimated from the average pixels within ROIs drawn around the tumor, 
inflammation or muscle on transverse slices of the reconstructed image sets. 
 
III. Results 
Chemistry and radiochemistry 
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        The synthetic scheme of precursor EC-Tyrosine is shown in Fig. 2.1. The 
structure and purity of EC-Tyrosine were confirmed by 1H- and 13C- NMR, mass 
spectra, and HPLC, respectively. The total synthesis yield of EC-Tyrosine was 79.5% 
(3-step). The 1H- and 13C-NMR results were 1H-NMR (D2O, δ/ppm): 7.01 (d, 2H, 
phenyl ring), 6.79 (d, 2H, phenyl ring), 3.94 (dd, 2H, O-CH2), 3.27(t, 2H, CHN), 2.87 
(d, 2H, PhCH2-), 2.68-2.40(m, 8H, -CH2-), 1.88(m, 2H, C-CH2-C). 13C-NMR (D2O, 
δ/ppm): 182.22, 182.22, 180.16, 156.69, 130.85, 130.50, 130.50, 114.85, 114.85, 
66.89, 62.66, 57.35, 57.35, 46.28, 39.61, 34.29, 28.31, 28.20. 
        Precursor EC-Tyrosine could be labeled with 99mTc
 
with high radiochemical 
purities (> 95%). The partition coefficient value (logP) of 99mTc-EC-Tyrosine was -
2.02±0.168.  
 
 
 
 
 
 
 
Figure 2.1. Synthetic scheme of precursor EC-Tyrosine. 
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 In Vitro Cellular Uptake Studies 
        The cellular uptake kinetics of 99mTc-EC-Tyrosine, 99mTc-EC, and 18F-FDG 
using 13762 rat breast tumor cells is shown in Fig. 2.2. The uptake of 99mTc-EC-
Tyrosine into the tumor cells increased rapidly, and reached 1.02%Uptake at 4 h. In 
addition, the %Uptake of 99mTc-EC-Tyrosine was much higher than that of 18F-FDG 
and the negative control 99mTc-EC. 
 
 
 
 
 
Figure 2.2. Time course of 99mTc-EC-Tyrosine, 99mTc-EC and 18F-FDG uptake in rat 
breast tumor cell line 13762 (0– 240 min). Data are expressed in mean ± S.D. 
percentage of cellular uptake (%Uptake). 
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Competitive Inhibition Study of 99mTc-EC-Tyrosine 
        After incubated with L-tyrosine at 10-100 times as high as the concentrations 
of EC-Tyrosine, 99mTc-EC-Tyrosine showed a significantly decreased uptake, 
especially for 50 and 100 times concentration groups (Fig. 2.3). These results 
suggest that 99mTc-EC-Tyrosine is transported at least partially via the same 
transporter system LAT as L-tyrosine is. 
 
 
 
 
Figure 2.3. Competitive inhibition uptake of 99mTc-EC-Tyrosine by L-tyrosine in rat 
breast tumor cell line 13762 up to 1 h. A set of concentrations of L-tyrosine [10X–
100X of EC-Tyrosine concentration (8 mg/well)] were used. Data are expressed in 
mean ± S.D. percentage of cellular uptake (%Uptake). 
*P<0.05 compared with the control group. 
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Blood clearance 
        The blood clearance curve for 99mTc-EC-Tyrosine in normal Fischer 344 rats 
(n=3) is shown in Fig. 2.4. The plasma half-life of the distribution phase (t1/2 α) was 
13.68±1.067 min, and that of the elimination phase (t1/2 β) was 117.51±5.727 min. 
 
 
 
 
 
 
 
 
 
Figure 2.4. Blood clearance (%ID/g) of 99mTc-EC-Tyrosine in normal female Fischer 
344 rats (n=3). The data represent the mean radioactivity expressed as a percentage 
of the injected dose per gram of blood ± S.D.  
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 In Vivo Tissue Distribution Study of 99mTc-EC-Tyrosine 
        The tissue distribution results of 99mTc-EC-Tyrosine and 18F-FDG in the normal 
Fischer 344 rats are shown in Tables 2.1 and 2.2, respectively. Low thyroid and 
stomach uptake of 99mTc-EC-Tyrosine was observed, suggesting its high stability in 
vivo. In addition, kidneys had high uptake of 99mTc-EC-Tyrosine at all time-points.   
 
Table 2.1. Biodistribution of 99mTc-EC-Tyrosine in normal Fischer 344 female rats. 
 
Each rat received 99mTc-EC-Tyrosine (25 µCi, intravenously). Each value is percent of 
injected dose per gram weight (n= 3)/time interval. Each data represents mean of three 
measurements with standard deviation. 
 
 
 
%ID/g 30 MIN 120 MIN 240 MIN
blood 0.96 ±0.076 0.41 ±0.039 0.23 ±0.006
heart 0.24 ±0.007 0.12 ±0.011 0.08 ±0.009
lung 0.47 ±0.041 0.33 ±0.001 0.20 ±0.025
thyroid 0.43 ±0.036 0.24 ±0.001 0.11 ±0.002
pancreas 0.21 ±0.018 0.17 ±0.016 0.10 ±0.007
liver 1.47 ±0.045 2.42 ±0.075 0.97 ±0.007
spleen 0.47 ±0.054 1.41 ±0.117 0.62 ±0.036
kidney 11.12 ±0.545 16.50 ±0.395 11.13 ±0.234
stomach 0.27 ±0.006 0.19 ±0.002 0.08 ±0.000
intestine 1.13 ±0.009 0.33 ±0.023 0.17 ±0.017
muscle 0.10 ±0.009 0.05 ±0.006 0.03 ±0.000
bone&joint 0.28 ±0.021 0.10 ±0.003 0.07 ±0.009
brain 0.04 ±0.003 0.01 ±0.001 0.01 ±0.001
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Table 2.2. Biodistribution of 18F-FDG in normal Fischer 344 female rats. 
 
Each rat received 18F-FDG (25 µCi, intravenously). Each value is percent of injected dose 
per gram weight (n =3)/time interval. Each data represents mean of three measurements 
with standard deviation. 
 
 
 
 
 
 
 
 
 
 
%ID/g 30 MIN 60 MIN 120 MIN
blood 0.40 ±0.042 0.13 ±0.006 0.06 ±0.002
heart 1.57 ±0.056 1.38 ±0.126 1.08 ±0.068
lung 0.55 ±0.056 0.42 ±0.024 0.46 ±0.027
thyroid 1.07 ±0.080 1.04 ±0.040 1.05 ±0.069
pancreas 0.26 ±0.028 0.21 ±0.006 0.20 ±0.016
liver 0.40 ±0.048 0.16 ±0.006 0.13 ±0.012
spleen 0.82 ±0.081 0.74 ±0.032 0.86 ±0.071
kidney 0.71 ±0.051 0.37 ±0.012 0.24 ±0.018
stomach 0.61 ±0.078 0.44 ±0.031 0.39 ±0.030
intestine 0.69 ±0.068 0.53 ±0.035 0.52 ±0.025
muscle 0.33 ±0.040 0.34 ±0.027 0.74 ±0.024
bone& joint 0.33 ±0.036 0.44 ±0.065 0.50 ±0.034
brain 2.00 ±0.149 1.99 ±0.046 1.39 ±0.086
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 Planar Scintigraphic Imaging Study 
        The selected planar scintigraphic images of 99mTc-EC-Tyrosine at 30 min, 2h, 
and 4 h in breast tumor-bearing rats are shown in Fig. 2.5. Tumors were clearly 
detected by 99mTc-EC-Tyrosine at all time-points. The T/M ratios at 30 min, 2h, and 
4 h were 4.54, 5.25, and 4.92, respectively. Tumor %IDs at these three time-points 
were 2.16%, 1.62%, and 1.57%, respectively (Fig. 2.5). 
 
 
 
 
 
Figure 2.5. Planar scintigraphy of 99mTc-EC-Tyrosine at 30 – 240 min in rat breast 
tumor-bearing rats (T: tumor).  
T/M = 4.54 T/M = 4.92 T/M = 5.25
Tumor %ID: 2.16 Tumor %ID: 1.62 Tumor %ID: 1.57
30 MIN 240 MIN120 MIN
T
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In Vivo Uptake Blocking Study 
        The liver, kidneys, tumor, and muscle %IDs, as well as the ratios of these 
organs to muscle before and after in vivo blocking by unlabeled L-Tyrosine were 
listed in Table 2.3 and 2.4. The organ-to-muscle ratios of 99mTc-EC-Tyrosine after 
using the blocking agent L-tyrosine decreased at all time intervals compared to the 
control group. However, this observation was not because of the decreased uptake 
of liver, kidneys or tumor, but due to the increased 99mTc-EC-Tyrosine uptake by 
muscle (Table 2.3).  99mTc-EC-Tyrosine uptake at tumor site could only be blocked 
at 30 min, suggesting that 99mTc-EC-Tyrosine and unlabeled L-Tyrosine might be 
uptaken via the same amino acid transporter LAT very rapidly. 
 
 
Table 2.3. Percentage of injected dose (%ID) of selected organs before and after in vivo 
blocking of 99mTc-EC-Tyrosine by unlabeled L-Tyrosine in mammary tumor-bearing rats. 
Red font indicates the decreased %ID when compared to the corresponding control 
group. Blue shading indicates P<0.05 when compared to the corresponding control 
group (n=3/group/time interval). 
 
 
 
%ID
30 min 2 hr 4hr
Control Block Decrease Control Block Decrease Control Block Decrease
Liver 6.23±0.34 6.67±0.42 -7.06% 6.06±0.27 5.11±0.12 15.68% 5.90±0.54 5.62±0.51 4.75%
Kidney 11.36±0.53 9.87±0.61 13.12% 9.73±0.31 8.36±0.29 14.08% 7.46±0.21 10.62±0.17 -42.36%
Tumor 1.36±0.08 1.28±0.15 5.88% 0.82±0.06 0.95±0.09 -15.85% 0.69±0.11 0.83±0.05 -20.29%
Muscle 0.32±0.03 0.58±0.05 -81.25% 0.24±0.06 0.36±0.05 -50.00% 0.15±0.02 0.23±0.04 -53.33%
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Table 2.4. Selected organ to muscle ratios before and after in vivo blocking of 99mTc-EC-
Tyrosine by unlabeled L-Tyrosine in mammary tumor-bearing rats. Red font indicates the 
decreased %ID when compared to the corresponding control group. Blue shading 
indicates P<0.05 when compared to the corresponding control group (n=3/group/time 
interval). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ratio
30 min 2 hr 4hr
Control Block Decrease Control Block Decrease Control Block Decrease
Liver/Muscle 19.7±1.1 11.5±0.6 41.62% 61.7±1.7 14.2±0.4 76.99% 39.7±2.4 24.7±1.6 37.78%
Kidney/Muscle 36.0±1.4 17.0±1.2 52.78% 99.1±3.2 23.3±2.4 76.49% 50.2±3.4 46.6±3.1 7.17%
Tumor/Muscle 4.25±0.12 2.21±0.23 48.00% 3.42±0.25 2.64±0.29 22.81% 4.64±0.06 3.64±0.35 21.55%
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Tumor and Inflammation Uptake Comparison In Vivo 
                The representative planar scintigraphic images of 99mTc-EC-Tyrosine, as 
well as the micro-PET images of 18F-FDG in breast tumor and inflammation-bearing 
rats are shown in Fig. 2.6 and Fig. 2.7, respectively. The T/M of 99mTc-EC-Tyrosine 
at each time interval was much higher than I/M. In addition, the T/I of 99mTc-EC-
Tyrosine at the last time-point was even higher than that of 18F-FDG (2.47 vs. 1.80), 
which suggested that 99mTc-EC-Tyrosine could differentiate tumor from 
inflammation very well. 
 
 
 
Figure 2.6. Planar scintigraphic images of 99mTc-EC-Tyrosine at 30 – 240 min in rat 
breast tumor and inflammation-bearing rats (T: tumor, I: inflammation). The tumor-to-
muscle ratios (T/Ms), inflammation-to-muscle ratios (I/Ms), and tumor-to-
inflammation ratios (T/Is) are listed below the figure. 
30 min 2 hr 4 hr
T/M 4.30 8.36 4.64
I/M 3.02 4.31 1.88
T/I 1.43 1.94 2.47
30 MIN 240 MIN120 MIN
T
I
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Figure 2.7. microPET images of 18F-FDG at 30 – 90 min in rat breast tumor and 
inflammation-bearing rats (T: tumor, I: inflammation). The tumor-to-muscle ratios 
(T/Ms), inflammation-to-muscle ratios (I/Ms), and tumor-to-inflammation ratios (T/Is) 
are listed below the figure. 
Transverse Saggital Axial
T I
T I
T I
30 min
60 min
90 min
30 min 60 min 90 min
T/M 5.88 7.54 4.90
I/M 3.43 3.77 2.72
T/I 1.71 1.99 1.80
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IV. Discussion 
        In the present study, we report the synthesis of 99mTc-labeled tyrosine using 
EC as a chelator, and its potentials in breast cancer diagnosis by using the breast 
tumor models in vitro and in vivo are evaluated.  
        For chemical synthesis, the precursor EC-Tyrosine was successfully 
synthesized with an overall yield of 79.5%. Since the starting material N-t-
Butoxycarbonyl-L-tyrosine methyl ester was commercially available, it took only 
three steps to obtain the final product EC-Tyrosine. The mild aqueous solution 
instead of the traditional organic solution was used for the coupling reaction of EC 
with N-t-Butoxycarbonyl-O-[3-Br-propyl]-L-tyrosine methyl ester (compound 1), 
which is a very efficient method. In this reaction, the molar ratio of EC and N-t-
Butoxycarbonyl-O-[3-Br-propyl]-L-tyrosine methyl ester (compound 1) was 
controlled accurately in 2:1 in order to avoid each EC conjugating with more than 
one Tyrosine. The structure of EC-Tyrosine was well confirmed with the NMR and 
mass spectra results; therefore, tyrosine was assured to be conjugated with EC 
specifically on the nitrogen atom, but not on the sulfur atom. 
        When the precursor EC-Tyrosine was labeled with 99mTc, the radiochemical 
purity was more than 95%. Since 99mTc-EC-Tyrosine is a kit-product and labeled 
without any further purification, the radiochemical yield was assumed to be identical 
to its radiochemical purity. The partition coefficient value (logP) of 99mTc-EC-
Tyrosine was slightly lower than its α-methyl derivative 99mTc-EC-AMT (-2.02±0.168 
vs.-1.14±0.072, reported in Chapter 3), which supports our hypothesis. It is well-
known that the lower logP indicates the lower lipophilicity of the compound. In our 
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hypothesis, we speculated that the lipophilicity of tyrosine-based radiotracer could 
be increased by adding a methyl group on its α-carbon.    
        In cellular uptake study, 99mTc-EC-Tyrosine was taken up rapidly by rat 
mammary tumor cells, and the %Uptake of 99mTc-EC-Tyrosine was significantly 
higher than that of the negative control 99mTc-EC, suggesting high specificity of 
99mTc-EC-Tyrosine in tumor uptake. Besides, 99mTc-EC-Tyrosine even has higher 
uptake than 18F-FDG in this in vitro breast cancer model. In competitive inhibition 
study, 99mTc-EC-Tyrosine uptake was significantly inhibited by L-tyrosine at 50x and 
100x concentrations, which suggests that 99mTc-EC-Tyrosine is transported at least 
partially via the same transporter system LAT that L-tyrosine exploits. These 
findings were consistent with those of many other radiolabeled tyrosine analogs. For 
instance, 11C/14C-tyrosine[119], 123I/125I-labeled AMT[56, 120], 18F-labeled 
tyrosine[121], AMT[76], and fluoroethyltyrosine (18F-FET) [114] have been proven to 
be predominantly transported via amino acid transporter LAT. Since the increased 
expression level of LAT has been observed in various types of tumors[38], 
upregulated LAT is a suitable target for tumor imaging.  
         For in vivo evaluation, 99mTc-EC-Tyrosine had a relatively fast blood clearance 
in normal Fischer 344 rats (Fig. 2.4). Biodistribution study showed that 99mTc-EC-
Tyrosine had high uptake in kidneys of normal rats (Table 2.1), which was 
consistent with the imaging findings in the breast tumor-bearing rats (Fig. 2.5).This 
may partially due to the characteristics of EC given that 99mTc-EC itself is known as 
a renal tubular imaging agent[122]. In addition, the similar results were observed in 
99mTc-labeled EC-chelated AMT analogue 99mTc-EC-AMT (reported in Chapter 3). 
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Compared to 99mTc-EC-AMT, 99mTc-EC-Tyrosine had even higher kidney uptake, 
which may be owing to its lower lipophilicity. The compound with lower lipophilicity 
is more water soluble, therefore, is more likely to be metabolized and excreted by 
kidneys. Furthermore, Shikano et al. confirmed that the uptake of 123I-labeled AMT 
(123I-AMT) into normal human renal proximal tubule epithelial cells could be 
significantly inhibited by BCH, an LAT specific inhibitor[123]. This result suggests 
that LAT is involved in radiolabled tyrosine uptake in kidneys. To ascertain whether 
99mTc-EC-Tyrosine uptake is mediated specifically by LAT, the in vivo uptake 
blocking studies using the unlabeled L-Tyrosine as the competitive inhibitor were 
conducted (Table 2.3 and 2.4). Although the organ-to-muscle ratios of 99mTc-EC-
Tyrosine after using the blocking agent L-tyrosine decreased at all time intervals 
compared to the control group, this observation was caused by the increased 99mTc-
EC-Tyrosine uptake in muscle (Table 2.3).  99mTc-EC-Tyrosine uptake at tumor site 
could only be blocked at 30 min, suggesting that 99mTc-EC-Tyrosine and unlabeled 
L-Tyrosine might be uptaken via the same amino acid transporter LAT very rapidly. 
These in vivo findings were coherent with the in vitro competitive inhibition results. 
        The most important finding in our study was the high suitability of 99mTc-EC-
Tyrosine to differentiate tumor from inflammation. The T/M of 99mTc-EC-Tyrosine at 
each time-point was much higher than I/M. In addition, the T/I of 99mTc-EC-Tyrosine 
at the last time-point was even higher than that of 18F-FDG (2.47 vs. 1.80). Since 
one of the biggest limitations of 18F-FDG in clinic is that it cannot distinguish tumor 
from inflammatory site very well, 99mTc-EC-Tyrosine may promise an ideal 
alternative to 18F-FDG in future.  
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        In summary, EC-Tyrosine was synthesized and labeled with 99mTc readily and 
efficiently with high radiochemical purity. In vitro cellular uptake study demonstrated 
that 99mTc-EC-Tyrosine transport involved amino acid transporter system LAT. Due 
to its simple chemical synthesis procedure, high cost effectiveness of the isotope, 
and comparatively high tumor/muscle uptake ratios in planar imaging, 99mTc-EC-
Tyrosine has great potential for breast cancer imaging, especially in differential 
diagnosis of tumor from inflammation. By taking the advantages of the coordination 
capability of chelator, EC-Tyrosine could chelate various radioisotopes for either 
imaging or therapy in the future.  
 
 
 
 
 
 
 
 
 
 
 
 
55 
 
CHAPTER 3   Development of 99mTc-EC-AMT for breast cancer 
imaging (partially adapted from [124]) 
I. Introduction 
        
18F-FDG-PET is a gold standard for tumor detection and staging in clinic. 
Unfortunately, 18F-FDG has several limitations that give rise to false 
positive/negative diagnosis and poor predictive value of tumor response to 
chemo/radio therapy[125]. 18F-FDG has poor contrast in brain tumor due to the high 
uptake of glucose in both normal and neoplastic brain tissues[111], and it has poor 
differentiation of tumor from inflammatory tissue, because of the high uptake of 18F-
FDG in granulocytes and macrophages[112, 113]. Radiolabeled amino acids show 
relatively low accumulation in normal tissues, rather high accumulation in tumor 
tissue, and rapid blood clearance[32]. These radiolabeled amino acids are attractive, 
since the main determinant of their uptake is amino acid transporters that are 
generally upregulated in cancer cells[76, 126]. Upregulated amino acid transporters 
indirectly reflect elevated cell proliferation[127], and assessment of their activities 
promises potential applications in differential diagnosis and prediction of early 
treatment response. Among all radiolabeled amino acids, aromatic amino acids are 
more suitable for tumor imaging due to easier chemical modification and 
characterization. However, aromatic amino acids tend to be decarboxylated[128], 
which reduces its ability to enter cells via amino acid transporters. Placing a methyl 
group at the alpha position could slower its metabolic process, thus, extensive 
amount of effort was directed towards the 18F- and 123/124I-labeled α-carbon-
methylated aromatic amino acids such as 2-[18F]fluoromethyl-L-phenylalanine[129], 
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2- and 3-L-[18F]fluoro-α-methyl tyrosine (18F-FAMT)[75, 81, 130], and 123I-labeled L-
3-[123I]iodo-α-methyltyrosine (123I-AMT)[56].  
        Clinical study in lung cancer patients showed that 18F-FAMT had no false-
positives in detecting primary tumors and lymph node metastases, and was able to 
improve the diagnostic performance in non-small cell lung cancer[81]. 18F-FAMT 
has been proven to be transported into the tumor cells solely via the LAT system, 
especially the LAT1 subtype[76]. LAT is the only system that can transport large 
neutral amino acids with aromatic rings such as tyrosine, phenylalanine, and 
tryptophan[38, 41]. LAT family is known to form heterodimers, which contain a 
chaperone-like heavy chain 4F2hc, and a 12-time transmembrane light chain that is 
unique to each subtype[117]. Previous clinical studies showed that uptake of 18F-
FAMT in tumors was positively correlated with LAT1 expression and cell 
proliferation[81]. Although application of 18F-FAMT-PET shows very promising 
clinical results, its radiosynthesis yield is relatively low, and the cost of using PET 
isotope 18F is prohibitive. Therefore, it is desirable to develop a radiotracer with 
simpler chemistry and affordable isotope, which can be used clinically in most major 
medical facilities.  
        
99mTc is an ideal radioisotope for diagnostic imaging studies, due to its physical 
characteristics. It emits a 140 keV gamma ray in 89% abundance [103], which is 
commonly used by SPECT. The half-life of 99mTc is 6.02 h, which can provide serial 
images and therefore overcome the drawback of 18F. Diaminodithiol (N2S2) 
compounds are known to form considerably stable Tc (V) O-complexes owing to the 
efficient binding of the oxotechnetium group to two thiols and two amine nitrogen 
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atoms[107]. EC is the most successful example of N2S2 chelates[106, 131]. 
Previously, we reported that EC-conjugates can be labeled with 99mTc via a peptide 
bond efficiently with high radiochemical purity, and the complex remains stable[131]. 
Here, we report the synthesis of 99mTc-labeled AMT using EC as a chelator and 
evaluation of its potential use in breast tumor imaging.  
 
II. Materials and methods 
Chemicals and Analysis 
        All chemicals and sources used here were previously described in Chapter 2. 
 
Synthesis of Precursor EC-AMT  
a) α-Methyl tyrosine ethylester (compound 1). 
        Thionyl chloride (18 mL; 0.24 mol) was added to α-methyltyrosine (15.0 g; 0.08 
mol) in anhydrous ethanol (100 mL) at 0 oC. The mixture was refluxed at 80-90 oC 
overnight with stirring. After cooling, the solvent was evaporated in vacuo to dryness. 
A saturated solution of NaHCO3 (150 mL) was added to the residue. White solid 
was filtered and washed with water and recrystallized in ethanol and water to yield 
15.7 g (91.7%). MS(m/z): 224.23 [M]+. 
 
b) N-t-Butoxycarbonyl-α-methyltyrosineethylester (compound 2).  
        Compound 1 (15.48 g; 69.35 mmol) was dissolved in anhydrous 
dichloromethane (200 mL). Di-tert-butyl dicarbonate (15.14 g; 69.35 mmol) and 
NaHCO3 (58.3 g, 0.69 mol) were added. Reaction mixture was stirred overnight at 
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50 oC, and the white solid was removed by filtration. The solution was washed with 
water and dried over anhydrous MgSO4. The product was purified by column 
chromatography using a silica gel column, and eluted with hexane/ethyl acetate (5:2 
v/v) to yield 8.97 g (40%). MS(m/z): 346.16 [M+Na]+. 
 
c) N-t-Butoxycarbonyl-O-[3-Br-propyl]-α-methyl tyrosine ethylester 
(compound 3).  
        Compound 2 (9.42 g; 0.029 mol) was dissolved in acetone (200 mL). 1,3-
dibromopropane (11.0 mL; 0.115 mol) and K2CO3 (10.0 g; 0.178 mol) were added 
under nitrogen. The reaction mixture was refluxed at 70-80 oC overnight. After 
cooling and filtration, the solvent was removed under reduced pressure, and the 
residue was dissolved in chloroform. The residue was washed with water and dried 
with anhydrous MgSO4. The product was purified by column chromatography using 
a silica gel column, eluted with hexane/ethyl acetate (4:1 v/v) to yield 11.0 g (86%). 
Ms(m/z): 445.10 [M]+. 
 
d) N-t-Butoxycarbonyl-O-[3-(N-Ethylenedicysteine) propyl]-α-methyl tyrosine 
(compound 4).  
        EC (3.33 g, 12.4 mmol) was dissolved in water (50 mL), and the pH was 
adjusted to pH 9-10 by NaOH (1N). Compound 3 (3.86 g, 8.69 mmol) in ethanol (80 
mL) was added to the above solution, followed by adding K2CO3 (8.6 g, 62.2 mmol). 
Reaction mixture was then heated at 90 oC overnight. After cooling, the solvent was 
removed under reduced pressure, and the residue was dissolved in chloroform (50 
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mL). The residue was washed with water, dried with anhydrous MgSO4, and 
evaporated to dryness. Without further purification, the compound 4 was used for 
following steps. 
 
e) O-[3-(N-Ethylenedicysteine) propyl]-α-methyl tyrosine (EC-AMT) (compound 
5). 
        The crude product of compound 4 (2.5 g, 0.04 mol) was dissolved in 
dichloromethane (50 mL). Hydrobromic acid (48%, 4.5 mL) was added dropwisely 
to the solution over 30 min periods at room temperature with stirring. After filtration, 
the white solid was washed with ethanol and recrystallized in water to yield 2.08g 
(86%).   
 
f) Rhenium- O-[3-(N-Ethylenedicysteine) propyl]-α-methyl tyrosine (Re-EC-
AMT) (compound 6). 
        An ethanol solution (10 mL) containing trichlorooxobis (triphenylphosphine) 
rhenium (V) (110 mg, 0.13 mmol) was added to an aqueous solution (10 mL) with 
EC-AMT (66 mg, 0.13 mmol) and potassium hydroxide (120 mg, 1.3 mmol), 
followed by refluxing at 90 °C for 1 h. The color of reaction mixture changed from 
green to yellow. After cooling and filtration, the ethanol was removed in vacuo. The 
remaining aqueous solution was acidified to pH 4 with 1N HCl. The yellow solid 
product (Re-EC-AMT) formed immediately was collected and recrystallized from 
water. Ms (m/z): 739.29 [M+HCl] +. 
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Radiolabeling of EC-AMT and EC with 99mTc 
        EC-AMT (1 mg) was dissolved in 0.2 mL sterile water, followed by adding tin (II) 
chloride (0.1 mL, 1 mg/mL). For EC labeling, EC (0.5 mg) was dissolved in 0.2mL 
sterile water by adding 10 uL of 1N NaOH (pH=9). Required amount of Na99mTcO4 
was added to EC or EC-AMT solution (pH 7.4). Radiochemical purity was 
determined by radio-HPLC (High performance liquid chromatography; Waters, 
Milford, MA), eluted with acetonitrile: water (7:3) using a flow rate of 0.5 mL/min. 
 
Determination of the Partition Coefficient 
        To determine the lipophilicity, 20 µL of 99mTc-EC-AMT was added into an equal 
volume mixture of 1-octanol and sterile water in a centrifuge tube. The mixture was 
vortexed at room temperature for 1 min and then centrifuged at 5000 rpm for 5 min. 
From each phase, 0.1 mL of the aliquot was taken out and the radioactivity was 
measured by gamma counter (Cobra Quantum; Packard, MN). The measurement 
was repeated for three times, and care was taken to avoid cross contamination 
between the phases. The partition coefficient value, expressed as logP, was 
calculated using the following equation: 
LogP = Log (radioactivity in 1-octanol layer / radioactivity in sterile water layer) 
 
In Vitro Cellular Uptake Studies 
        Rat breast tumor cell line 13762 (American Type Culture Collection, Rockville, 
MD) was selected and the same cell line was used to create the animal model for in 
vivo evaluation. Cells were maintained in Dulbecco’s modified Eagle’s medium and 
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nutrient mixture F-12 Ham (DMEM/F12; GIBCO, Grand Island, NY) at 37 oC in a 
humidified atmosphere containing 5% CO2. Cells were plated onto 6-well tissue 
culture plates (2x105 cells/well) and incubated with 99mTc-EC-AMT (0.05 mg/well, 8 
uCi/well), 99mTc-EC (0.025 mg/well, 8 uCi/well) or 18F-FDG (8 uCi/well) for 0-4 h. 
After incubation, cells were washed with ice-cold PBS twice and detached by 
treating them with 0.5 mL of trypsin for 5 min. Cells were then collected and the 
radioactivity was measured with gamma counter (Cobra Quantum; Packard, MN). 
Data were expressed in mean ±S.D. percent of cellular uptake (%Uptake) in 
triplicate. 
 
Competitive Inhibition Study of 99mTc-EC-AMT 
        To investigate the transport mechanisms of 99mTc-EC-AMT, the competitive 
inhibition study using L-tyrosine was conducted. Rat breast tumor cells were co-
incubated with 99mTc-EC-AMT (8 µg/well, 8 µCi/well) and L-tyrosine for up to 1 h. A 
set of concentrations of L-tyrosine (10x, 50x, and 100x of the EC-AMT 
concentration) were used. After incubation, cells were washed with ice-cold PBS 
twice and detached by treating them with 0.5 mL of trypsin for 5 min. Cells were 
then collected and the radioactivity was measured by gamma counter. Data were 
expressed in mean ±S.D. percent of cellular uptake (%Uptake) in triplicate. 
 
Blood Clearance 
        All animal work was carried out in the Small Animal Imaging Facility (SAIF) at 
UTMDACC under a protocol approved by Institutional Animal Care and Use 
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Committee (IACUC). For blood clearance analysis, three normal female Fischer 344 
rats (150±25 g) (Harlan Sprague-Dawley, Indianapolis, IN) were intravenously 
injected with 30 µCi 99mTc-EC-AMT. Blood samples were drawn through lateral tail 
vein at several time-points from 5 min to 24 h (n=3/rat) by microliter pipettes (10 µL). 
The blood samples were measured for radioactivity by gamma counter, and then 
were calculated as percentage of the injected dose per gram of blood (%ID/g). 
 
In vivo Tissue Distribution Studies 
        Tissue distribution studies of 99mTc-EC-AMT (study I, n=9) and 18F-FDG (study 
II, n=9) were conducted by using normal female Fischer 344 rats (150±25 g, n=18). 
For each compound, the rats were divided into three groups for three time intervals 
(0.5, 2, 4 h for 99mTc-EC-AMT; 0.5, 1, 2 h for 18F-FDG; n=3/time point). The injection 
activity was 25±0.5 µCi/rat intravenously. At each time interval, the rats were 
sacrificed, and the selected tissues were excised, weighed and measured for 
radioactivity by gamma counter. Each sample was calculated as percentage of the 
injected dose per gram of tissue wet weight (%ID/g). Counts from a diluted sample 
of the original injection were used as reference.  
 
Planar Scintigraphic Imaging Study 
        Female Fischer 344 rats were inoculated subcutaneously with 0.1 mL of breast 
tumor cells 13762 suspension in PBS (105 cells/rat) into the right legs. Planar 
scintigraphic imaging of 99mTc-EC-AMT was performed 12-14 days after inoculation 
when tumors reached approximately 1 cm in diameter. Planar scintigraphic images 
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were obtained using M-CAM (Siemens Medical Solutions, Hoffman Estates, IL) 
equipped with a Low Energy High Resolution collimator. Anesthetized breast tumor-
bearing rats were injected intravenously with 99mTc-EC-AMT (0.3 mg/rat, 300 µCi/rat; 
n=3). The images were acquired up to 4 h post-administration of tracers. Computer 
outlined regions of interest (ROIs in counts per pixel) between tumor and muscle 
were used to calculate tumor/muscle (T/M) ratios. Percentage of the injected dose 
(%ID) of tumor was also calculated from the reference standard, which was 1/10 of 
the original injection activity. 
 
In Vivo Uptake Blocking Study 
        To ascertain whether 99mTc-EC-AMT uptake is mediated specifically by LAT, in 
vivo blocking studies using the unlabeled L-Tyrosine as the competitive inhibitor 
was conducted. The same animal model used in the planar scintigraphic imaging 
study was employed. Unlabeled L-Tyrosine (50 mg/kg) dissolved in 0.3 mL saline 
(pH adjusted to 2-3) was administered intravenously to mammary tumor–bearing 
rats 1 h prior to 99mTc-EC-AMT injection. Planar scintigraphic images were acquired 
up to 4 h, and ROIs of liver, kidneys, tumor, and muscle were used to calculate the 
ratios of liver/muscle, kidney/muscle, and tumor/muscle, respectively. In 
addition, %IDs of liver, kidneys, tumor, and muscle were calculated from the 
reference standard, which was 1/10 of the original injection activity. The results 
were compared with those from the rats injected with 99mTc-EC-AMT alone (control). 
 
Tumor and Inflammation Uptake Comparison In Vivo 
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        To investigate whether 99mTc-EC-AMT can differentiate tumor from the 
inflammatory tissue, a rat model bearing both mammary tumor and turpentine oil-
induced inflammation was created. 13762 rat mammary tumor cells (105 cells/0.1 
mL PBS/rat) were inoculated into the right calf muscles of the female Fischer 344 
rats. After the tumors reached to 1 cm in diameter, turpentine oil (0.1 mL/rat) was 
injected into the left calf muscles of the rats to induce inflammation. The 
anesthetized rats (n=3) were injected intravenously with 99mTc-EC-AMT 24 h after 
the turpentine injection. Planar scintigraphic images were acquired up to 4 h, and 
ROIs of tumor, inflammation, and muscle were used to calculate the tumor-to-
muscle ratios (T/Ms), inflammation-to-muscle ratios (I/Ms), and tumor-to-
inflammation ratios (T/Is), respectively. Same animal model was used to evaluate 
18F-FDG. Micro-PET imaging of 18F-FDG was performed using R4 micro-PET 
scanner (Concorde Microsystems, TN). The rats were injected intravenously with 
18F-FDG (500 uCi/rat, n=3), and dynamic PET scans were obtained for 90 min with 
a spatial resolution of 2.2 mm. PET images were reconstructed by using the 
ordered subset expectation maximization (OSEM) algorithm. T/Ms, I/Ms and T/Is 
ratios were calculated based on the regional radioactivity concentrations (µCi/cm3) 
that were estimated from the average pixels within ROIs drawn around the tumor, 
inflammation or muscle on transverse slices of the reconstructed image sets.  
 
III. Results 
Chemistry 
        EC-AMT was synthesized via a five-step procedure. The synthetic scheme is 
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shown in Fig.3.1. The structures and purities of EC-AMT and Re-EC-AMT were 
confirmed by 1H- and 13C- NMR, mass spectra, and HPLC. For EC-AMT, the 1H- 
and 13C-NMR results were 1H NMR (D2O, δ/ppm): 7.10 (d, 2H, phenyl ring), 6.79 (d, 
2H, phenyl ring), 3.96 (dd, 2H, O-CH2), 3.09(t, 1H, CHN), 2.87 (d, 2H, PhCH2-), 
2.68-2.40(m, 8H, -CH2-), 1.88(m, 2H, C-CH2-C), 1.13[s, 9H, C(CH3)3]. 13C NMR 
(D2O, δ/ppm): 184.22, 180.16, 156.69, 131.11, 130.40, 114.65, 66.90, 62.69, 59.31, 
57.28, 46.33, 45.47, 34.29, 28.35, 28.23, 25.76, 16.85. For Re-EC-AMT, the 1H- 
and 13C-NMR results are 1H NMR (D2O, δ/ppm): 7.02 (d, 2H, phenyl ring), 6.87 (d, 
2H, phenyl ring), 4.05 (t, 2H, O-CH2),3.17-3.00(m, 3H, CHN, PhCH2), 2.73-2.50 (m, 
8H, -CH2-), 1.96(m, 2H, C-CH2-C), 1.38[s, 3H, CH3].  
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Figure 3.1. Synthetic scheme of precursor EC-AMT and cold standard reference 
compound rhenium (Re) EC-AMT. 
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99mTc-labeled EC-AMT was obtained with high radiochemical purity (95%) (Fig. 
3.2). The retention time of 99mTc-EC-AMT matched to that of the cold reference 
standard Re-EC-AMT (Fig. 3.2). The partition coefficient value (logP) of 99mTc-EC-
AMT was -1.14±0.072.  
 
 
 
Figure 3.2.  High performance liquid chromatography analysis of 99mTc-EC-AMT and 
Re-EC-AMT at a flow rate of 0.5 mL/min using a C-18 reverse column under UV 
absorbance of 274 nm. 
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In Vitro Cellular Uptake Studies 
        The cellular uptake kinetics of 99mTc-EC-AMT, 99mTc-EC, and 18F-FDG using 
rat breast tumor cell line 13762 is shown in Fig. 3.3. The uptake of 99mTc-EC-AMT 
into the 13762 mammary tumor cells increased rapidly, and reached 1.85%Uptake 
at 4 h. In addition, the %Uptake of 99mTc-EC-AMT was dramatically higher than that 
of 18F-FDG and the negative control 99mTc-EC. 
 
 
 
 
 
 
 
 
Figure 3.3. Time course of 99mTc-EC-AMT, 99mTc-EC and 18F-FDG uptake in rat breast 
tumor cell line 13762 (0– 240 min). Data are expressed in mean ± S.D. percentage of 
cellular uptake (%Uptake). 
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Competitive Inhibition Study of 99mTc-EC-AMT 
        After incubating the 13762 rat mammary tumor cells with L-tyrosine at 10-100 
times as high as the concentrations of EC-AMT, these tumor cells showed a 
significantly decrease in 99mTc-EC-AMT uptake (Fig. 3.4). These results suggest 
that 99mTc-EC-AMT is transported at least partially via the same transporter system 
LAT that L-tyrosine exploits. 
 
 
 
 
Figure 3.4. Competitive inhibition uptake of 99mTc-EC-AMT by L-tyrosine in rat breast 
tumor cell line 13762 up to 1 h. A set of concentrations of L-tyrosine [10X–100X of 
EC-AMT concentration (8 mg/well)] were used. Data are expressed in mean ± S.D. 
percentage of cellular uptake (%Uptake). 
*P<0.05 compared with the control group. 
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Blood Clearance 
        The blood clearance curve for 99mTc-EC-AMT in normal Fischer 344 rats (n=3) 
is shown in Fig. 3.5. The plasma half-life of the distribution phase (t1/2 α) was 
9.41±0.202 min, and that of the elimination phase (t1/2 β) was 98.75±5.377 min. 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. Blood clearance (%ID/g) of 99mTc-EC-AMT in normal female Fischer 344 
rats (n=3). The data represent the mean radioactivity expressed as a percentage of 
the injected dose per gram of blood ± S.D.  
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In Vivo Tissue Distribution Studies 
        The tissue distribution results of 99mTc-EC-AMT and 18F-FDG in the normal 
Fischer 344 rats are shown in Tables 3.1 and 3.2, respectively. Low thyroid and 
stomach uptake of 99mTc-EC-AMT was observed, suggesting its high stability in vivo.   
 
Table 3.1. Biodistribution of 99mTc-EC-AMT in normal Fischer 344 female rats. 
 
Each rat received 99mTc-EC-AMT (25 µCi, intravenously). Each value is percent of injected 
dose per gram weight (n= 3)/time interval. Each data represents mean of three 
measurements with standard deviation. 
 
 
 
 
 
%ID/g 30 MIN 120 MIN 240 MIN
blood 0.64 ±0.047 0.41 ±0.019 0.17 ±0.004
heart 0.19 ±0.005 0.11 ±0.004 0.05 ±0.002
lung 0.44 ±0.038 0.29 ±0.012 0.14 ±0.004
thyroid 0.28 ±0.029 0.22 ±0.038 0.09 ±0.008
pancreas 0.15 ±0.016 0.10 ±0.003 0.06 ±0.001
liver 2.03 ±0.180 1.48 ±0.079 1.07 ±0.155
spleen 0.56 ±0.053 0.54 ±0.027 0.48 ±0.054
kidney 8.56 ±0.966 9.01 ±0.212 8.43 ±0.171
stomach 0.28 ±0.070 0.12 ±0.006 0.08 ±0.012
intestine 0.89 ±0.107 0.81 ±0.490 0.13 ±0.009
muscle 0.10 ±0.017 0.05 ±0.001 0.02 ±0.001
bone& joint 0.09 ±0.016 0.07 ±0.010 0.06 ±0.005
brain 0.02 ±0.003 0.02 ±0.003 0.01 ±0.001
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Table 3.2. Biodistribution of 18F-FDG in normal Fischer 344 female rats. 
 
Each rat received 18F-FDG (25 µCi, intravenously). Each value is percent of injected dose 
per gram weight (n =3)/time interval. Each data represents mean of three measurements 
with standard deviation. 
 
 
 
 
 
 
 
 
 
 
%ID/g 30 MIN 60 MIN 120 MIN
blood 0.40 ±0.042 0.13 ±0.006 0.06 ±0.002
heart 1.57 ±0.056 1.38 ±0.126 1.08 ±0.068
lung 0.55 ±0.056 0.42 ±0.024 0.46 ±0.027
thyroid 1.07 ±0.080 1.04 ±0.040 1.05 ±0.069
pancreas 0.26 ±0.028 0.21 ±0.006 0.20 ±0.016
liver 0.40 ±0.048 0.16 ±0.006 0.13 ±0.012
spleen 0.82 ±0.081 0.74 ±0.032 0.86 ±0.071
kidney 0.71 ±0.051 0.37 ±0.012 0.24 ±0.018
stomach 0.61 ±0.078 0.44 ±0.031 0.39 ±0.030
intestine 0.69 ±0.068 0.53 ±0.035 0.52 ±0.025
muscle 0.33 ±0.040 0.34 ±0.027 0.74 ±0.024
bone& joint 0.33 ±0.036 0.44 ±0.065 0.50 ±0.034
brain 2.00 ±0.149 1.99 ±0.046 1.39 ±0.086
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Planar Scintigraphic Imaging Study  
        The selected planar scintigraphic images of 99mTc-EC-AMT at 30 min, 2h, and 
4 h in breast tumor-bearing rats are shown in Fig. 3.6. Tumors were clearly detected 
by 99mTc-EC-AMT at all time-points. The T/M ratios at 30 min, 2h, and 4 h were 6.94, 
8.77, and 10.59, respectively. Tumor %IDs at these three time-points were 1.87%, 
1.25%, and 1.17%, respectively (Fig. 3.6). 
 
 
 
 
 
 
Figure 3.6. Planar scintigraphy of 99mTc-EC-AMT at 30 – 240 min in rat breast tumor-
bearing rats (T: tumor).  
T/M = 6.94 T/M = 10.59 T/M = 8.77
Tumor %ID: 1.87 Tumor %ID: 1.25 Tumor %ID: 1.17
30 MIN 240 MIN120 MIN
T
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In Vivo Uptake Blocking Study 
        The liver, kidneys, tumor, and muscle %IDs, as well as the ratios of these 
organs to muscle before and after in vivo blocking by unlabeled L-Tyrosine were 
listed in Table 3.3 and 3.4. At 30 min, 99mTc-EC-AMT uptake in liver, kidney, and 
tumor decreased by 9.8%, 47.9%, and 23.9% respectively by using the blocking 
agent L-Tyrosine. However, after 90 min, no significant blocking effect was 
observed. (Results at 4 h are not shown). These results suggest that 99mTc-EC-AMT 
at least partially utilizes the same transport system LAT as L-Tyrosine does, and is 
taken by tumor rapidly.  
 
 
Table 3.3. Percentage of injected dose (%ID) of selected organs before and after in vivo 
blocking of 99mTc-EC-AMT by unlabeled L-Tyrosine in mammary tumor-bearing rats. Red 
font indicates the decreased %ID when compared to the corresponding control group. 
Blue shading indicates P<0.05 when compared to the corresponding control group 
(n=3/group/time interval). 
 
 
 
%ID
30 min 2 hr 4hr
Control Block Decrease Control Block Decrease Control Block Decrease
Liver 6.98±0.44 6.91±0.56 1.00% 8.02±0.21 6.47±0.16 19.33% 6.66±0.53 5.41±0.15 18.77%
Kidney 28.0±1.6 16.0±2.6 42.86% 34.2±3.6 25.3±4.0 26.02% 23.5±1.7 20.2±0.6 14.04%
Tumor 1.28±0.04 1.07±0.09 16.41% 0.77±0.08 0.74±0.05 3.90% 0.68±0.09 0.70±0.11 -2.94%
Muscle 0.28±0.03 0.30±0.03 -7.14% 0.21±0.03 0.20±0.04 4.76% 0.13±0.01 0.13±0.02 0.00%
75 
 
Table 3.4. Selected organ to muscle ratios before and after in vivo blocking of 99mTc-EC-
AMT by unlabeled L-Tyrosine in mammary tumor-bearing rats. Red font indicates the 
decreased %ID when compared to the corresponding control group. Blue shading 
indicates P<0.05 when compared to the corresponding control group (n=3/group/time 
interval). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ratio
30 min 2 hr 4hr
Control Block Decrease Control Block Decrease Control Block Decrease
Liver/Muscle 25.4±1.8 22.9±1.5 9.84% 38.7±1.8 34.7±0.9 10.34% 50.6±3.3 41.5±2.1 26.90%
Kidney/Muscle 101.8±1.7 53.0±1.2 47.94% 165.3±5.7 135.9±10.3 17.79% 178.7±14.4 154.5±6.9 8.19%
Tumor/Muscle 4.64±0.54 3.54±0.32 23.71% 3.74±0.16 3.70±0.23 1.07% 5.15±0.17 5.33±0.41 -7.52%
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Tumor and Inflammation Uptake Comparison In Vivo 
        The representative planar scintigraphic images of 99mTc-EC-AMT, as well as 
the micro-PET images of 18F-FDG in breast tumor and inflammation-bearing rats 
are shown in Fig. 3.7 and Fig. 3.8, respectively. The T/M of 99mTc-EC-AMT at each 
time-point was relatively lower than I/M ratio. Furthermore, the T/I of 99mTc-EC-AMT 
was also lower than that of 18F-FDG. These results suggested that 99mTc-EC-AMT 
could not differentiate tumor from inflammation very well in this tumor model. 
 
 
 
 
Figure 3.7. Planar scintigraphic images of 99mTc-EC-AMT at 30 – 240 min in rat breast 
tumor and inflammation-bearing rats (T: tumor, I: inflammation). The tumor-to-muscle 
ratios (T/Ms), inflammation-to-muscle ratios (I/Ms), and tumor-to-inflammation ratios 
(T/Is) are listed below the figure. 
30 min 2 hr 4 hr
T/M 2.68 2.51 2.75
I/M 3.17 3.10 3.02
T/I 0.84 0.81 0.91
30 MIN 240 MIN120 MIN
T I
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Figure 3.8. microPET images of 18F-FDG at 30 – 90 min in rat breast tumor and 
inflammation-bearing rats (T: tumor, I: inflammation). The tumor-to-muscle ratios 
(T/Ms), inflammation-to-muscle ratios (I/Ms), and tumor-to-inflammation ratios (T/Is) 
are listed below the figure. 
Transverse Saggital Axial
T I
T I
T I
30 min
60 min
90 min
30 min 60 min 90 min
T/M 5.88 7.54 4.90
I/M 3.43 3.77 2.72
T/I 1.71 1.99 1.80
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IV. Discussion 
        The present study investigated the imaging capability of 99mTc-EC-AMT in 
breast tumor models in vitro and in vivo. For chemical synthesis, the precursor EC-
AMT was successfully synthesized with an overall yield of 23%. Since the chelator 
EC was unprotected during the coupling reaction with AMT, each EC molecule 
could be conjugated with more than one AMT. Moreover, AMT might not only be 
conjugated with EC specifically on the nitrogen atom, but also on the sulfur atom. 
Those two potential problems could be readily solved by conducting the coupling 
reaction in the mild aqueous solution instead of the organic one. In addition, the 
molar ratio of EC and N-t-Butoxycarbonyl-O-[3-Br-propyl]-α-methyl tyrosine 
ethylester (compound 3) was controlled accurately in 2:1 under this aqueous 
solution. Furthermore, the structure of EC-AMT was well confirmed from the 1H-
NMR and mass spectra results. 
        When label the precursor EC-AMT with 99mTc, the radiochemical purity was 
95%. In respect that 99mTc-EC-AMT is a kit-product and labeled without any further 
purification, the radiochemical yield was assumed to be identical to its 
radiochemical purity (95%). Re-EC-AMT was synthesized as the reference standard 
for the structure confirmation of 99mTc-EC-AMT. In periodic table, Tc is a second-
row transition element in Group 7 and right above rhenium. Hence, Tc is very 
similar to Re in terms of chemistry, and they are known to have identical 
coordination parameters with the same ligand such as AMT[103]. From the HPLC 
results, the retention time of 99mTc-EC-AMT matched to that of Re-EC-AMT, 
suggested the radiochemical structure of 99mTc-EC-AMT was correct. In addition, 
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one radioisotopic form of Re, 188Re, is commonly used for the internal radionuclide 
therapy[132]. Therefore, 188Re-EC-AMT might be valuable in the treatment of breast 
cancer, while 99mTc-EC-AMT could be used to diagnose the cancer and monitor 
treatment response in the future. 
        In cellular uptake study, 99mTc-EC-AMT was taken up rapidly by rat mammary 
tumor cells, and the %Uptake of 99mTc-EC-AMT was significantly higher than that of 
the negative control 99mTc-EC, suggesting high specificity of 99mTc-EC-AMT in tumor 
uptake. Besides, 99mTc-EC-AMT has much higher uptake than 18F-FDG in this in 
vitro breast cancer model. In competitive inhibition study, 99mTc-EC-AMT uptake 
could be significantly inhibited by L-tyrosine, which suggests that 99mTc-EC-AMT is 
transported at least partially via the same transporter system LAT that L-tyrosine 
exploits. Our findings were consistent with other reported studies regarding 
radiolabeled tyrosine analogs. For instance, 11C/14C-tyrosine[119], 123I/125I-labeled 
AMT[56, 120], 18F-labeled tyrosine[121], AMT[76], and fluoroethyltyrosine (18F-FET) 
[114] have been proven to be predominantly transported via amino acid transporter 
LAT. Increased expression level of LAT has been observed in various types of 
tumors[38], therefore, upregulated LAT is a suitable target for tumor imaging.  
         For in vivo evaluation, 99mTc-EC-AMT had a relatively fast blood clearance in 
normal Fischer 344 rats (Fig. 3.5). Biodistribution study showed that 99mTc-EC-AMT 
had high uptake in kidneys of normal rats (Table 3.1), which was consistent with the 
imaging results of breast tumor-bearing rats (Fig. 3.6).This may due to the 
characteristics of EC given that 99mTc-EC is a well-known renal tubular imaging 
agent[122]. In addition, Moore et al. reported that AMT itself, an inhibitor of tyrosine 
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hydroxylase, could not be excreted from kidneys and hence crystallized in the 
proximal tubules because of its poor solubility at the hydrogen ion concentrations of 
body fluids (pH 5-8)[133]. Furthermore, Shikano et al. confirmed that the uptake of 
123I-labeled AMT (123I-AMT) into normal human renal proximal tubule epithelial cells 
could be significantly inhibited by BCH, an LAT specific inhibitor[123]. This result 
suggests that LAT is involved in 123I-AMT uptake in kidneys. To ascertain whether 
99mTc-EC-AMT uptake is mediated specifically by LAT, we then conducted in vivo 
uptake blocking studies using the unlabeled L-Tyrosine as the competitive inhibitor 
(Table 3.3 and 3.4). 99mTc-EC-AMT uptake in liver, kidney, and tumor were 
significantly blocked at early time-points, which suggested that both 99mTc-EC-AMT 
and unlabeled L-Tyrosine were rapidly uptaken via amino acid transporter LAT. 
These in vivo findings were coherent with the in vitro competitive inhibition results.  
        In planar imaging studies shown in Fig. 3.6, tumors could be clearly detected 
by 99mTc-EC-AMT at all time-points. Because of the washout of non-specific uptake, 
T/M ratios of 99mTc-EC-AMT increased from 6.94 to 10.59, which were even much 
higher than those of 18F-FDG. The T/M ratios of 18F-FDG in the same animal model 
were 5.88, 7.54 and 2.87 for 30 min, 60 min and 120 min, respectively (images not 
shown). Nevertheless, we found that 99mTc-EC-AMT was not superior to 18F-FDG in 
differentiating tumor from inflammation in this animal model because the T/Is of 
99mTc-EC-AMT were lower than those of 18F-FDG. In this study, we used turpentine 
to induce inflammation chemically. In future, we may need to create and test 99mTc-
EC-AMT in another animal model using radiation to induce inflammation so it can 
more similarly mimic the patients undergoing radiation therapy.    
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        In summary, EC-AMT was synthesized and labeled with 99mTc readily and 
efficiently with high radiochemical purity. In vitro cellular uptake study demonstrated 
that 99mTc-EC-AMT transport involved amino acid transporter system LAT. Although 
it cannot differentiate breast tumor from chemical-induced inflammation very well, 
99mTc-EC-AMT has great potential for breast cancer imaging given its simple 
chemical synthesis procedure, more cost effectiveness of the isotope, and high 
tumor/muscle uptake ratios in planar imaging. By taking the advantages of the 
coordination capability of the chelator, EC-AMT could chelate various radioisotopes 
for either imaging or therapy in the future.  
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CHAPTER 4   Development of 99mTc-N4-Tyrosine for breast cancer 
imaging 
I. Introduction 
       18F-FDG, an 18F-labeled glucose analog, is a gold standard for PET in cancer 
diagnosis[2]. However, 18F-FDG-PET has several limitations that give rise to false 
positive/negative diagnosis and poor predictive value of tumor response to 
chemo/radio therapy[125]. For instance, 18F-FDG cannot distinguish tumor from 
inflammatory or normal brain tissues because both sites have high glucose 
consumption. Therefore, radiolabeled amino acids have been developed as an 
alternative to 18F-FDG. Their use in tumor detection is based on an increased 
uptake of amino acids in tumor cells, which is assumed to reflect an enhanced 
amino acid transporter, metabolism, and protein synthesis[114]. Among all 
radiolabeled amino acids, aromatic ones such as tyrosine and its derivatives are 
more suitable given their easier chemistry alterations and favorable biological 
characterizations. To date, tyrosine and its α-methyl substituted analog AMT have 
been successfully labeled with 11C[115, 116], 18F[75, 81] and 124/125I[65] for PET 
imaging, as well as 123/131I[56] for SPECT imaging, respectively. Most of those 
radiolabeled tyrosine analogs show promising preclinical and clinical results in 
tumor imaging, especially in brain tumor diagnosis. In addition, they have been 
proven to accumulate into the tumor cells predominantly via LAT, which is the only 
system that can transport large neutral amino acids with aromatic rings such as 
tyrosine, phenylalanine, and tryptophan[38, 41]. LAT, especially its subtype LAT1, is 
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an ideal target for tumor imaging because it is up-regulated and highly expressed in 
many cancer cell lines and correlated with tumor growth[117, 118].  
        Although the existing radiolabeled tyrosine and its derivatives have shown very 
promising clinical outcomes, most of them require an on-site cyclotron to produce 
the radioisotope, which is inconvenient and expensive. Besides, the half-life of the 
radioisotopes are either too short (i.e. 20 min for 11C) or too long (i.e. 57.4 days for 
125I). Furthermore, iodine-labeled compounds are not stable in vivo because of 
deiodination. So far, 18F has the most appropriate half-life (110 min), however, the 
radiosynthesis yield of 18F-labeled radiotracers appear to be relatively low because 
of its electrophillic fluorination and tedious purification. Therefore, it is desirable to 
develop a radiotracer with simpler chemistry and affordable isotope, which can be 
used clinically in most major medical facilities. 99mTc is an ideal radioisotope for 
diagnostic imaging studies, due to its physical characteristics. It emits a 140 keV 
gamma ray in 89% abundance [103], which is commonly used by gamma imaging 
and SPECT. The half-life of 99mTc is 6.02 h, which can provide serial images and 
therefore overcome the drawback of 18F. Unlike most of the cyclotron-produced 
radionuclides that utilize the covalent chemistry for labeling, 99mTc requires a 
“chelator” to conjugate the radioisotope with the target ligand. The nitrogen, oxygen 
and sulfur combination have been shown to be stable chelators for 99mTc such as N4 
(e.g. DOTA, cyclam-14), N3S (e.g. MAG-3), N2S2 (e.g. ECD), NS3, S4 (e.g. sulfur 
colloid), diethylenetriamine pentaacetic acid (DTPA), O2S2 (e.g. DMSA), and 
hydrazinenicotinamide (HYNIC)[68, 101-105]. By taking the advantage of using the 
chelator, we could label several other radioisotopes such as Gallium-68, Indium-111, 
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or Rhenium-188 with the same ligand for diagnostic and therapeutic applications in 
future[105, 107]. Here, we report the synthesis of 99mTc-labeled tyrosine using N4 
cyclam as a chelator and evaluate its potential in breast tumor imaging.  
 
II. Materials and methods 
Chemicals and Analysis 
        All chemicals and sources used here were previously described in Chapter 2.  
 
Synthesis of Precursor N4-Tyrosine  
a) N-t-Butoxycarbonyl-O-[3-Br-propyl]-L-tyrosine methyl ester 1.  
        N-t-Butoxycarbonyl-L-tyrosine methyl ester (25 g; 0.085 mol) was dissolved in 
acetone (300 mL). 1,3-dibromopropane (17.3 mL; 0.169 mol) and K2CO3 (58 g; 
0.420 mol) were added under nitrogen. The reaction mixture was refluxed at 80 oC 
overnight. After cooling and filtration, the solvent was removed under reduced 
pressure, and the residue was dissolved in chloroform. The residue was washed 
with water and dried with anhydrous MgSO4. The product was purified by column 
chromatography using a silica gel column, eluted with hexane/ethyl acetate (2:1 v/v) 
to yield 33.3 g (94.6%). Ms (m/z): 440.09 [M+Na]+. 
 
b) N1, N4-dioxylyl-1,4,8,11-tetraazabicyclotetradecane (N1,N4-cyclooxamide) 
2. 
        N4 cyclam (15.00 g; 74.88 mmol) was dissolved in 150 mL of anhydrous 
ethanol, and diethyl oxalate (10.94 g; 74.88 mmol) was added. The reaction mixture 
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was refluxed 18 h at 75 0C. The solvent was rotary evaporated and the crude 
product was recrystallized in acetone : ethanol to yield white crystals of N1,N4-
dioxylyl-1,4,8,11-1,5,8,12-tetraazabicyclotetradecane (N1,N4-cyclooxamide) 2 . Yield: 
13.64 g (17.31 mmol, 72.00 %). Ms (m/z) = 255.33 [M]+. 
 
c) N-t-Butoxycarbonyl-O-[3-( N1,N4-dioxylyl-1,4,8,11-
tetraazabicyclotetradecane)-propyl]- tyrosine methylester 3. 
        Compound 2 (0.625 g; 2.46 mmol) was dissolved in 20 mL of anhydrous DMF 
and reacted with a solution of compound 1 (1.06 g; 2.46 mmol) in 40 mL of DMF 
under nitrogen atmosphere. The mixture was refluxed at 75 0C for 18 hours, and 
then cooled to room temperature. The solvent was removed in vacuo. The residue 
was dissolved in 30 mL chloroform, washed with water and 12 mL of 1M Na2CO3, 
and then separated for the organic layer. The crude compound was purified via a 
silica gel column using chloroform: methanol (9:1) solution. Yield: 0.6489 g (1.052 
mmol, 42.76%).  
 
d) O-[3-(N1,N4-dioxylyl-1,4,8,11-tetraazabicyclotetradecane)-propyl]-
tyrosine methylester 4. 
        Compound 3 (0.6 g; 1 mmol) was dissolved in anhydrous dichloromethane (15 
mL), and 2.5 mL of trifluoroacetic acid was added. The solution was stirred 
overnight at room temperature, and the solvents were removed in vacuo.  
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e) O-[3-(1,4,8,11-tetraazabicyclohexadecane)-propyl]-tyrosine (N4-
Tyrosine) 5. 
        Compound 4 (0.25 g; mmol) was dissolved in 5 mL water, and 2.5 mL of 10N 
NaOH was added to it. The solution was stirred and refluxed overnight at 90 0C, and 
the solvent was evaporated in vacuo. The crude compound was then dissolved in 5 
mL water, and pH of the solution was neutralized to pH=7 by adding 5 M HCl. The 
final solution was lyophilized overnight to obtain white powder, which was then 
dissolved in 25 mL anhydrous methanol, filtered, evaporated, and lyophilized to 
obtain off-white powder.   
 
Radiolabeling of N4-Tyrosine with 99mTc 
        N4-Tyrosine (1 mg) was dissolved in 0.2 mL sterile water, followed by adding 
tin (II) chloride (0.1 mL, 1 mg/mL). Required amount of Na99mTcO4 was added to 
N4-Tyrosine solution. Radiochemical purity was determined by radio-HPLC (Waters, 
Milford, MA), eluted with acetonitrile: water (7:3) using a flow rate of 0.5 mL/min. 
 
Determination of the Partition Coefficient 
        To determine the lipophilicity, 20 µL of 99mTc-N4-Tyrosine was added into an 
equal volume mixture of 1-octanol and sterile water in a centrifuge tube. The 
mixture was vortexed at room temperature for 1 min and then centrifuged at 5000 
rpm for 5 min. From each phase, 0.1 mL of the aliquot was taken out and the 
radioactivity was measured by gamma counter (Cobra Quantum; Packard, MN). 
The measurement was repeated for three times, and care was taken to avoid cross 
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contamination between the phases. The partition coefficient value, expressed as 
logP, was calculated using the following equation: 
LogP = Log (radioactivity in 1-octanol layer / radioactivity in sterile water layer) 
 
   In Vitro Cellular Uptake Studies 
        Rat breast tumor cell line 13762 (American Type Culture Collection, Rockville, 
MD) was selected because the same cell line was used to create the animal model 
for in vivo evaluation. Cells were maintained in Dulbecco’s modified Eagle’s medium 
and nutrient mixture F-12 Ham (DMEM/F12; GIBCO, Grand Island, NY) at 37 oC in 
a humidified atmosphere containing 5% CO2. Cells were plated onto 6-well tissue 
culture plates (2x105 cells/well) and incubated with 99mTc-N4-Tyrosine (0.05 mg/well, 
8 uCi/well), 99mTc-N4 (0.025 mg/well, 8 uCi/well) or 18F-FDG (8 uCi/well) for 0-4 h. 
After incubation, cells were washed with ice-cold PBS twice and detached by 
treating them with 0.5 mL of trypsin for 5 min. Cells were then collected and the 
radioactivity was measured with gamma counter (Cobra Quantum; Packard, MN). 
Data were expressed in mean ±S.D. percent of cellular uptake (%Uptake) in 
triplicate. 
 
In Vitro Competitive Inhibition Study  
        To investigate the transport mechanisms of 99mTc-N4-Tyrosine, the competitive 
inhibition study using L-tyrosine was conducted. Rat breast tumor cells were co-
incubated with 99mTc-N4-Tyrosine (8 µg/well, 8 µCi/well) and L-tyrosine for up to 1 h. 
A set of concentrations of L-tyrosine (10-1000x of the N4-Tyrosine concentration) 
88 
 
were used. After incubation, cells were washed with ice-cold PBS twice and 
detached by treating them with 0.5 mL of trypsin for 5 min. Cells were then collected 
and the radioactivity was measured by gamma counter. Data were expressed in 
mean ±S.D. percent of cellular uptake (%Uptake) in triplicate. 
 
Blood Clearance 
        All animal work was carried out in the Small Animal Imaging Facility (SAIF) at 
UTMDACC under a protocol approved by Institutional Animal Care and Use 
Committee (IACUC). For blood clearance analysis, three normal female Fischer 344 
rats (150±25 g) (Harlan Sprague-Dawley, Indianapolis, IN) were intravenously 
injected with 30 µCi 99mTc-N4-Tyrosine. Blood samples were drawn through lateral 
tail vein at several time-points from 5 min to 24 h (n=3/rat) by microliter pipettes (10 
µL). The blood samples were measured for radioactivity by gamma counter, and 
then were calculated as percentage of the injected dose per gram of blood (%ID/g). 
 
In vivo Tissue Distribution Studies 
        Tissue distribution studies of 99mTc-N4-Tyrosine (study I, n=9) and 18F-FDG 
(study II, n=9) were conducted by using normal female Fischer 344 rats (150±25 g, 
n=18). For each compound, the rats were divided into three groups for three time 
intervals (0.5, 2, 4 h for 99mTc-N4-Tyrosine; 0.5, 1, 2 h for 18F-FDG; n=3/time point). 
The injection activity was 25±0.5 µCi/rat intravenously. At each time interval, the 
rats were sacrificed, and the selected tissues were excised, weighed and measured 
for radioactivity by gamma counter. Each sample was calculated as percentage of 
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the injected dose per gram of tissue wet weight (%ID/g). Counts from a diluted 
sample of the original injection were used as reference.  
 
Planar Scintigraphic Imaging Study 
        Female Fischer 344 rats were inoculated subcutaneously with 0.1 mL of breast 
tumor cells 13762 suspension in PBS (105 cells/rat) into the right legs. Planar 
scintigraphic imaging of 99mTc-N4-Tyrosine was performed 12-14 days after 
inoculation when tumors reached approximately 1 cm in diameter. Planar 
scintigraphic images were obtained using M-CAM (Siemens Medical Solutions, 
Hoffman Estates, IL) equipped with a Low Energy High Resolution collimator. 
Anesthetized breast tumor-bearing rats were injected intravenously with 99mTc-N4-
Tyrosine (0.3 mg/rat, 300 µCi/rat; n=3). The images were acquired up to 4 h post-
administration of tracers. Computer outlined regions of interest (ROIs in counts per 
pixel) between tumor and muscle were used to calculate tumor/muscle (T/M) ratios. 
Percentage of the injected dose (%ID) of tumor was also calculated from the 
reference standard, which was 1/10 of the original injection activity. 
 
In Vivo Uptake Blocking Study 
        To ascertain whether 99mTc-N4-Tyrosine uptake is mediated specifically by 
LAT, in vivo blocking studies using the unlabeled L-Tyrosine as the competitive 
inhibitor was conducted. The same animal model used in the planar scintigraphic 
imaging study was employed. Unlabeled L-Tyrosine (50 mg/kg) dissolved in 0.3 mL 
saline (pH adjusted to 2-3) was administered intravenously to mammary tumor–
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bearing rats 1 h prior to 99mTc-N4-Tyrosine injection. Planar scintigraphic images 
were acquired up to 4 h, and ROIs of liver, kidneys, tumor, and muscle were used to 
calculate the ratios of liver/muscle, kidney/muscle, and tumor/muscle, respectively. 
In addition, %IDs of liver, kidneys, tumor, and muscle were calculated from the 
reference standard, which was 1/10 of the original injection activity. The results 
were compared with those from the rats injected with 99mTc-N4-Tyrosine alone 
(control). 
 
Tumor and Inflammation Uptake Comparison In Vivo 
        To investigate whether 99mTc-N4-Tyrosine can differentiate tumor from the 
inflammatory tissue, a rat model bearing both mammary tumor and turpentine oil-
induced inflammation was created. 13762 rat mammary tumor cells (105 cells/0.1 
mL PBS/rat) were inoculated into the right calf muscles of the female Fischer 344 
rats. After the tumors reached to 1 cm in diameter, turpentine oil (0.1 mL/rat) was 
injected into the left calf muscles of the rats to induce inflammation. The 
anesthetized rats (n=3) were injected intravenously with 99mTc-N4-Tyrosine 24 h 
after the turpentine injection. Planar scintigraphic images were acquired up to 4 h, 
and ROIs of tumor, inflammation, and muscle were used to calculate the tumor-to-
muscle ratios (T/Ms), inflammation-to-muscle ratios (I/Ms), and tumor-to-
inflammation ratios (T/Is), respectively. Same animal model was used to evaluate 
18F-FDG. Micro-PET imaging of 18F-FDG was performed using R4 micro-PET 
scanner (Concorde Microsystems, TN). The rats were injected intravenously with 
18F-FDG (500 µCi/rat, n=3), and dynamic PET scans were obtained for 90 min with 
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a spatial resolution of 2.2 mm. PET images were reconstructed by using the 
ordered subset expectation maximization (OSEM) algorithm. T/Ms, I/Ms and T/Is 
ratios were calculated based on the regional radioactivity concentrations (µCi/cm3) 
that were estimated from the average pixels within ROIs drawn around the tumor, 
inflammation or muscle on transverse slices of the reconstructed image sets. 
 
III. Results 
Chemistry and Radiochemistry 
        Precursor N4-Tyrosine was synthesized via a five-step procedure and the total 
synthesis yield was 38%. The synthetic scheme is shown in Fig.4.1. The structure 
and purity of N4-Tyrosine was confirmed by 1H- and 13C- NMR, mass spectra, and 
HPLC. The 1H- and 13C-NMR results were 1H- NMR (D2O, δ/ppm): 7.18 (d, 2H, 
phenyl ring), 6.95 (d, 2H, phenyl ring), 4.073 (t, 2H, O-CH2), 3.43(t, 1H, CHN), 2.28-
3.00 (m, 2OH, OCH2 and NCH2-), 1.87-1.91(m, 2H, C-CH2-C), 1.68-1.79(m, 4H, C-
CH2-C). 13C- NMR (D2O, δ/ppm):162.88,156.72, 130.76, 117.57, 115.25, 68.55, 
57.29, 53.91, 51.56, 49.95, 49.17, 48.96, 48.24, 48.03, 46.80, 45.73, 45.35, 39.27, 
24.90, 24.31, 23.87. 
        Precursor N4-Tyrosine could be labeled with 99mTc successfully in a high 
radiochemical purity (>96%). The logP of 99mTc-N4-Tyrosine was -2.83±0.082.  
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Figure 4.1. Synthetic scheme of precursor N4-Tyrosine. 
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In Vitro Cellular Uptake Studies 
        The cellular uptake kinetics of 99mTc-N4-Tyrosine, 99mTc-N4, and 18F-FDG 
using rat breast tumor cells is shown in Fig. 4.2. There was a drastically increased 
uptake for 99mTc-N4-Tyrosine at 15-240 min, but not for 99mTc-N4 chelator itself, 
which suggested that 99mTc-N4-Tyrosine can enter and accumulate into tumor cells 
rapidly and specifically. In addition, the %Uptake of 99mTc-N4-Tyrosine was 
relatively higher than that of 18F-FDG. 
 
 
 
 
Figure 4.2. Time course of 99mTc-N4-Tyrosine, 99mTc-N4 and 18F-FDG uptake in rat 
breast tumor cell line 13762 (0– 240 min). Data are expressed in mean ± S.D. 
percentage of cellular uptake (%Uptake). 
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Competitive Inhibition Study of 99mTc-N4-Tyrosine 
         After co-incubated with L-tyrosine at 10-1000 times as high as the 
concentrations of N4-Tyrosine, 99mTc-N4-Tyrosine did not show any significantly 
decreased uptake at all concentrations. The 99mTc-N4-Tyrosine uptakes of selected 
concentrations are shown in Fig. 4.3. These results suggest that 99mTc-N4-Tyrosine 
may not share the same LAT transporter system as L-Tyrosine. 
 
 
 
 
Figure 4.3. Competitive inhibition uptake of 99mTc-N4-Tyrosine by L-tyrosine in rat 
breast tumor cell line 13762 up to 1 h. A set of concentrations of L-tyrosine [150-300X 
of N4-Tyrosine concentration (8 mg/well)] were used. Data are expressed in mean ± 
S.D. percentage of cellular uptake (%Uptake). 
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Blood Clearance 
        The blood clearance curve for 99mTc-N4-Tyrosine in normal Fischer 344 rats 
(n=3) is shown in Fig. 4.4. The plasma half-life of the distribution phase (t1/2 α) was 
9.31±0.759 min, and that of the elimination phase (t1/2 β) was 90.14±1.901 min. 
 
 
 
 
 
 
 
 
 
Figure 4.4. Blood clearance (%ID/g) of 99mTc-N4-Tyrosine in normal female Fischer 
344 rats (n=3). The data represent the mean radioactivity expressed as a percentage 
of the injected dose per gram of blood ± S.D.  
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In Vivo Tissue Distribution Studies 
        The tissue distribution results of 99mTc-N4-Tyrosine and 18F-FDG in the normal 
Fischer 344 rats are shown in Tables 4.1 and 4.2, respectively. Low thyroid and 
stomach uptake of 99mTc-N4-Tyrosine was observed, suggesting its high stability in 
vivo.    
 
Table 4.1. Biodistribution of 99mTc-N4-Tyrosine in normal Fischer 344 female rats. 
 
Each rat received 99mTc-N4-Tyrosine (25 µCi, intravenously). Each value is percent of 
injected dose per gram weight (n= 3)/time interval. Each data represents mean of three 
measurements with standard deviation. 
 
 
 
%ID/g 30 MIN 120 MIN 240 MIN
blood 0.88 ±0.040 0.20 ±0.018 0.17 ±0.009
heart 0.21 ±0.022 0.06 ±0.003 0.05 ±0.003
lung 0.50 ±0.023 0.19 ±0.011 0.14 ±0.006
thyroid 0.34 ±0.019 0.10 ±0.010 0.09 ±0.006
pancreas 0.17 ±0.017 0.07 ±0.012 0.05 ±0.002
liver 1.15 ±0.059 0.70 ±0.040 0.67 ±0.044
spleen 0.94 ±0.089 0.76 ±0.032 0.63 ±0.051
kidney 11.05 ±0.783 12.34 ±0.502 12.40 ±0.405
stomach 0.20 ±0.018 0.08 ±0.003 0.06 ±0.002
intestine 0.34 ±0.057 0.13 ±0.010 0.11 ±0.006
muscle 0.07 ±0.007 0.03 ±0.002 0.02 ±0.001
bone& joint 0.24 ±0.021 0.15 ±0.008 0.12 ±0.008
brain 0.03 ±0.001 0.02 ±0.001 0.01 ±0.001
97 
 
 
Table 4.2. Biodistribution of 18F-FDG in normal Fischer 344 female rats. 
 
Each rat received 18F-FDG (25 µCi, intravenously). Each value is percent of injected dose 
per gram weight (n =3)/time interval. Each data represents mean of three measurements 
with standard deviation. 
 
 
 
 
 
 
 
 
 
%ID/g 30 MIN 60 MIN 120 MIN
blood 0.40 ±0.042 0.13 ±0.006 0.06 ±0.002
heart 1.57 ±0.056 1.38 ±0.126 1.08 ±0.068
lung 0.55 ±0.056 0.42 ±0.024 0.46 ±0.027
thyroid 1.07 ±0.080 1.04 ±0.040 1.05 ±0.069
pancreas 0.26 ±0.028 0.21 ±0.006 0.20 ±0.016
liver 0.40 ±0.048 0.16 ±0.006 0.13 ±0.012
spleen 0.82 ±0.081 0.74 ±0.032 0.86 ±0.071
kidney 0.71 ±0.051 0.37 ±0.012 0.24 ±0.018
stomach 0.61 ±0.078 0.44 ±0.031 0.39 ±0.030
intestine 0.69 ±0.068 0.53 ±0.035 0.52 ±0.025
muscle 0.33 ±0.040 0.34 ±0.027 0.74 ±0.024
bone& joint 0.33 ±0.036 0.44 ±0.065 0.50 ±0.034
brain 2.00 ±0.149 1.99 ±0.046 1.39 ±0.086
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Planar Scintigraphic Imaging Study  
        The selected planar scintigraphic images of 99mTc-N4-Tyrosine at 30 min, 2h, 
and 4 h in breast tumor-bearing rats are shown in Fig. 4.5. Tumors could be clearly 
detected by 99mTc-N4-Tyrosine at all time-points. The T/M ratios at 30 min, 2h, and 
4 h were 5.12, 4.88, and 5.20, respectively. Tumor %ID at these three time-points 
were 1.82%, 1.87%, and 1.71%, respectively (Fig. 4.5). 
 
 
 
 
 
Figure 4.5. Planar scintigraphy of 99mTc-N4-Tyrosine at 30 – 240 min in rat breast 
tumor-bearing rats (T: tumor).  
T/M = 5.12 T/M = 5.20 T/M = 4.88
Tumor %ID: 1.82 Tumor %ID: 1.87 Tumor %ID: 1.71
30 MIN 240 MIN120 MIN
T
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In Vivo Uptake Blocking Study 
        The liver, kidneys, tumor, and muscle %ID of 99mTc-N4-Tyrosine, as well as the 
ratios of these organs to muscle before and after in vivo blocking by unlabeled L-
Tyrosine were listed in Table 4.3 and 4.4. By using the blocking agent L-Tyrosine, 
only kidneys uptake of 99mTc-N4-Tyrosine decreased at all time-points. The uptake 
(%ID) in liver, tumor and muscle even increased significantly. These results suggest 
that 99mTc-N4-Tyrosine may not utilize the same transport system LAT as L-
Tyrosine does in vivo.  
 
 
Table 4.3. Percentage of injected dose (%ID) of selected organs before and after in vivo 
blocking of 99mTc-N4-Tyrosine by unlabeled L-Tyrosine in mammary tumor-bearing rats. 
Red font indicates the decreased %ID when compared to the corresponding control 
group. Blue shading indicates P<0.05 when compared to the corresponding control 
group (n=3/group/time interval). 
 
 
 
 
%ID
30 min 2 hr 4hr
Control Block Decrease Control Block Decrease Control Block Decrease
Liver 8.76±0.42 9.59±0.62 -9.47% 9.69±0.5 10.24±0.36 -5.68% 7.9±0.42 10.1±1.5 -27.85%
Kidney 26.8±3.3 19.7±0.8 26.49% 30.7±2.1 26.0±2.4 15.31% 29.8±1.7 28.6±3.7 4.03%
Tumor 0.78±0.04 1.43±0.15 -83.33% 0.34±0.03 0.72±0.03 -111.76% 0.20±0.02 0.47±0.02 -135.01%
Muscle 0.15±0.03 0.31±0.01 -106.67% 0.08±0.01 0.13±0.02 -62.50% 0.06±0.01 0.09±0.015 50.00%
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Table 4.4. Selected organ to muscle ratios before and after in vivo blocking of 99mTc-N4-
Tyrosine by unlabeled L-Tyrosine in mammary tumor-bearing rats. Red font indicates the 
decreased %ID when compared to the corresponding control group. Blue shading 
indicates P<0.05 when compared to the corresponding control group (n=3/group/time 
interval). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ratio
30 min 2 hr 4hr
Control Block Decrease Control Block Decrease Control Block Decrease
Liver/Muscle 57.6±3.8 30.7±2.4 46.70% 117.1±4.7 80.6±2.5 31.17% 126.1±4.2 114.1±4.5 9.52%
Kidney/Muscle 176.0±7.1 63.3±3.6 64.03% 371.4±11.6 204.6±6.8 44.91% 473.5±14.1 321.6±3.7 32.08%
Tumor/Muscle 5.12±0.34 4.57±0.12 10.74% 4.11±0.18 5.68±0.39 -38.20% 3.24±0.25 5.34±0.13 -64.81%
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Tumor and Inflammation Uptake Comparison In Vivo 
        The selected planar scintigraphic images of 99mTc-N4-Tyrosine, as well as the 
micro-PET images of 18F-FDG in breast tumor and inflammation-bearing rats are 
shown in Fig. 4.6 and Fig. 4.7, respectively. The T/M of 99mTc-N4-Tyrosine at each 
time interval was relatively higher than I/M. Although T/I at all time-points were 
above 1, which meant tumor had higher uptake than the inflammation site, the ratios 
were lower than those of 18F-FDG. Therefore, these results suggested that 99mTc-
N4-Tyrosine could not differentiate tumor from inflammation very well. 
 
 
 
 
Figure 4.6. Planar scintigraphic images of 99mTc-N4-Tyrosine at 30 – 240 min in rat 
breast tumor and inflammation-bearing rats (T: tumor, I: inflammation). The tumor-to-
muscle ratios (T/Ms), inflammation-to-muscle ratios (I/Ms), and tumor-to-
inflammation ratios (T/Is) are listed below the figure. 
30 min 2 hr 4 hr
T/M 5.12 4.11 3.24
I/M 4.26 3.62 2.45
T/I 1.20 1.14 1.32
30 MIN 240 MIN120 MIN
T
I
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Figure 4.7. microPET images of 18F-FDG at 30 – 90 min in rat breast tumor and 
inflammation-bearing rats (T: tumor, I: inflammation). The tumor-to-muscle ratios 
(T/Ms), inflammation-to-muscle ratios (I/Ms), and tumor-to-inflammation ratios (T/Is) 
are listed below the figure. 
Transverse Saggital Axial
T I
T I
T I
30 min
60 min
90 min
30 min 60 min 90 min
T/M 5.88 7.54 4.90
I/M 3.43 3.77 2.72
T/I 1.71 1.99 1.80
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IV. Discussion 
        In the present study, we report the synthesis of 99mTc-labeled tyrosine using 
N4 cyclam as a chelator and evaluate its potential in breast cancer diagnosis by 
using the breast tumor models in vitro and in vivo.  
        For chemical synthesis, the precursor N4-Tyrosine was successfully 
synthesized via a five-step procedure with an overall yield of 38%. Since the starting 
material N-t-Butoxycarbonyl-L-tyrosine methyl ester was commercially available, the 
synthetic yield of N4-Tyrosine was much higher than that of its α-methyl derivative 
N4-AMT (14%). When the precursor N4-Tyrosine was labeled with 99mTc, the 
radiochemical purity was more than 96%. Since 99mTc-N4-Tyrosine is a kit-product 
and labeled without any further purification, the radiochemical yield was assumed to 
be identical to its radiochemical purity. As expected, the partition coefficient value 
(logP) of 99mTc-N4-Tyrosine was lower than that of its α-methyl derivative 99mTc-N4-
AMT (-2.83±0.082 vs. -2.02±0.168). As we know, the lower logP indicates the lower 
lipophilicity of the compound. The result verified our hypothesis that the lipophilicity 
of Tyrosine-based radiotracer could be increased by adding a methyl group on its α-
carbon.    
        In cellular uptake study, 99mTc-N4-Tyrosine was taken up rapidly by rat 
mammary tumor cells, and the %Uptake of 99mTc-N4-Tyrosine was significantly 
higher than that of the negative control 99mTc-N4, suggesting high specificity of 
99mTc-N4-Tyrosine in tumor uptake. Besides, 99mTc-N4-Tyrosine has even higher 
uptake than 18F-FDG in this in vitro breast cancer model. In competitive inhibition 
study using the same cell line, 99mTc-N4-Tyrosine uptake could not be inhibited by 
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L-Tyrosine at any concentration. Its uptake even increased by adding unlabeled L-
Tyrosine. Same results were observed in the in vivo uptake blocking studies using 
the unlabeled L-Tyrosine as the competitive inhibitor (Table 4.3 and 4.4). By using 
the blocking agent L-Tyrosine, only kidneys uptake of 99mTc-N4-Tyrosine decreased 
at all time-points. The uptake (%ID) in liver, tumor and muscle even increased 
significantly. Taken the in vitro and in vivo findings together, we conclude that 
99mTc-N4-Tyrosine may not be transported by the same amino acid transporter LAT 
as L-tyrosine. 
         
99mTc-N4-Tyrosine had a very fast blood clearance in normal Fischer 344 rats 
(Fig. 4.4). Biodistribution study showed that 99mTc-N4-Tyrosine had high uptake in 
kidneys of normal rats (Table 4.1), which was consistent with the imaging findings in 
the breast tumor-bearing rats (Fig. 4.5). This may due to the low lipophilicity of 
99mTc-N4-Tyrosine. In addition, it might be the characteristics of tyrosine because 
the similar results were also observed in our previously developed tyrosine-based 
radiotracer 99mTc-EC-AMT and 99mTc-EC-Tyrosine.   
        In planar imaging studies shown in Fig. 4.5, tumors could be clearly detected 
by 99mTc-N4-Tyrosine at all time-points; however, 99mTc-N4-Tyrosine appeared to be 
not ideal for differentiation of tumor from inflammation. Although T/Is were above 1 
at all time-points, which meant tumor had higher uptake than the inflammatory 
tissue, the ratios were less than those of 18F-FDG. In this study, we used turpentine 
to induce inflammation chemically. In future, we may need to test 99mTc-N4-Tyrosine 
in another animal model using the radiation to induce inflammation so it can more 
similarly mimic the patients undergoing radiation therapy.    
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        In summary, N4-Tyrosine was synthesized and labeled with 99mTc readily and 
efficiently with high radiochemical purity. Although in vitro and in vivo findings 
suggest that 99mTc-N4-Tyrosine does not use LAT system to enter the tumor lesion, 
it has high tumor/muscle uptake ratios and can detect breast tumor clearly. 
Furthermore, it is not suitable to use 99mTc-N4-Tyrosine to distinguish breast tumor 
from chemical-induced inflammation, however, we need to test its imaging potential 
in other inflammation models. 
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CHAPTER 5   Development of 99mTc-N4-AMT for breast cancer 
imaging (adapted partially from[134]) 
I. Introduction 
        18F-FDG, an 18F-labeled glucose analog, is the most common radiotracer for 
PET in cancer diagnosis[2]. However, 18F-FDG-PET has several limitations in 
practice, e.g. 18F-FDG cannot distinguish tumor from inflammatory or normal brain 
tissues. Therefore, 18F-labeled amino acid-based radiotracers have been reported 
as an alternative, which is based on the fact that tumor cells take up and consume 
more amino acids to maintain their sustained fast growth. Among those radiotracers, 
18F-labeled AMT has shown high tumor uptake and great ability to differentiate 
tumor tissue from inflammatory sites in brain tumors and squamous cell 
carcinoma[130]. 18F-AMT enters the tumor cells via LAT, which is the only system 
that can transport large neutral amino acids with aromatic rings[117]. LAT, 
especially its subtype LAT1, was reported to be highly expressed in many cancer 
cell lines and positively correlates with tumor growth[118, 135]. So far, 18F-AMT is 
the most suitable amino acid transporter-targeting radiotracer for tumor imaging, 
regardless of low synthesis yield and requirement of an on-site cyclotron to produce 
18F.  
        Although PET has emerged as an advanced imaging tool for cancer diagnosis, 
only a limited number of facilities around the world can afford complete operation of 
PET and cyclotron for the local production of short-lived positron-emitting 
radionuclides such as 11C and 18F. Therefore, mature technologies, i.e. SPECT and 
its combination with CT, still play important and irreplaceable roles in nuclear 
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imaging area[15]. The most common radionuclide for SPECT is 99mTc ( t1/2=6.02 h), 
which is produced by an in-house generator and does not require the cyclotron[14]. 
Due to their similar chemistry, the diagnostic radioisotope 99mTc and the therapeutic 
radioisotope 188Re could be labeled to the same ligand, which leads to the 
diagnostic/therapeutic matched pair. Unlike most of the cyclotron-produced 
radionuclides that utilize the covalent chemistry for labeling, 99mTc requires a 
“chelator” to conjugate the radionuclide with the target ligand. The nitrogen, oxygen 
and sulfur combination have been shown to be stable chelators for 99mTc such as N4 
(e.g. DOTA, cyclam-14), N3S (e.g. mercaptoacetyltriglycine), N2S2 (e.g. 
ethylenedicysteine diethyl ester), NS3, S4 (e.g. sulfur colloid), DTPA, O2S2 (e.g. 
dimercaptosuccinic acid), and HYNIC[68, 101-105].   
        Here, we report the synthesis of precursor O-[3-(1,4,8,11-
tetraazacyclotetradecan)-propyl]-α-methyl tyrosine (N4-AMT) and its radiolabeling 
with 99mTc. In vitro cellular uptake kinetics and planar scintigraphic imaging of 99mTc-
N4-AMT were also evaluated in breast cancer models.  
 
II. Materials and methods 
Chemicals and Analysis 
        All chemicals and sources used here were previously described in Chapter 2. 
 
Synthesis of Precursor N4-AMT 
a) α-Methyl tyrosine ethylester (Compound 2) 
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        Thionyl chloride (10 mL; 137.42 mmol) was added to a solution of α-
methyltyrosine 1 (10.00 g; 51.22 mmol) in anhydrous ethanol (60 mL) at 0 0C, and 
then heated at 78 0C for 4 h while stirring. After cooling, the volume of the reaction 
mixture was reduced to 20 mL, and then 10 mL of triethylamine was added into it. 
The mixture was poured into 100 mL of water and extracted with chloroform. The 
combined organic layers were dried over MgSO4. The desired compound was 
obtained as white solid. Yield: 9.00 g (40.32 mmol, 78.75 %). 1H-NMR (CDCl3) δ = 
7.02 (d, 2H, J = 8.4 Hz), 6.70 (d, 2H, J =  8.4 Hz), 4.22 (dd, 2H, J = 7.2 Hz, J = 7.8 
Hz), 3.14 (dd, 2H, J = 13.5 Hz, J = 13.5), 1.42 (s, 3H), 1.33 (t, 3H, J = 16.2 Hz) ppm. 
13C-NMR δ = 175.47, 156.36, 130.66, 126.39, 114.87, 61.05,  58.65, 45.29, 24.08, 
13.07 ppm, MS: m/z = 224.23 [M]+. 
 
b) N-t-Butoxycarbonyl-α-methyl tyrosine ethylester (Compound 3) 
        Compound 2 (2.09 g; 9.36 mmol) was dissolved in 40 mL of anhydrous DMF 
under nitrogen, and treated with triethylamine (2.78 mL; 20 mmol) while stirring. 
Ditertiarbutyl dicarbonate (3.27g; 15 mmol) was added to the reaction mixture and 
stirred over night at room temperature. The solvent was removed under reduced 
pressure to yield a residue, which was extracted with ethyl acetate and dried with 
anhydrous MgSO4. The extraction was filtered and evaporated to dryness to give 
yellow oil which was purified by loading on to a silica gel-packed column and eluted 
with hexane: ethyl acetate (5: 1.5 v/v). After evaporation of the solvent, yellow oil 3 
was obtained. Yield: 2.00 g (6.18 mmol, 66.20 %). 1H-NMR (CDCl3) δ = 6.97 (d, 2H, 
J = 8.4 Hz), 6.75 (d, 2H, J =  8.7 Hz), 4.22 (dd, 2H, J = 2.7 Hz, J = 7.2 Hz), 3.32 (dd, 
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2H, J = 15.0 Hz, J = 13.5), 1.55 (s, 3H), 1.48 (s, 9H), 1.32 (t, 3H, J = 18.0 Hz) ppm. 
13C-NMR δ = 174.16, 155.04, 154.51, 131.16, 128.50, 115.14, 77.25, 61.64, 60.54, 
40.99,  28.39, 23.55, 14.77 ppm, MS: m/z = 324.36 [M]+. 
 
c)  N-t-Butoxycarbonyl-O-[3-hydroxypropyl]-α-methyl tyrosine ethylester  
(Compound 4) 
        Sodium metal (0.09 g; 14.02 mmol) was dissolved in 30 mL of anhydrous 
ethanol with stirring under nitrogen. Compound 3 (1.00 g; 3.09 mmol) was dissolved 
in 50 mL of anhydrous ethanol and treated with sodium ethoxide solution, and 
refluxed for 2.5 h at 70 0C. 3-Bromopropanol (0.56 mL; 6.18 mmol) was added into 
the reaction mixture, which was heated continuously over night. The ethanol was 
removed under reduced pressure and replaced with 40 mL of ethyl acetate. The 
solution was then washed with water and dried over MgSO4.  After removal of the 
solvent, the crude compound was purified by a silica gel-packed column and eluted 
with hexane/ ethylacetate (2/1), giving 0.83 g (2.17 mmol, 71 % yield) of the product 
as clear yellow oil.  1H-NMR (CDCl3) δ = 7.01 (d, 2H, J = 6.3 Hz), 6.81 (d, 2H, J =  
6.6 Hz), 4.20 (dd, 2H, J = 5.1 Hz, J = 5.1 Hz), 4.12 (t, 2H, J = 15.0 Hz), 3.86 (t, 2H, 
J = 10.2 Hz), 3.16 (dd , J = 13.5 Hz, J = 12.9 Hz), 2.06 (m, 2H), 1.54 (s, 3H), 1.47 (s, 
9H), 1.31 (t, 3H, J = 12.3 Hz) ppm. 13C-NMR δ = 174.01, 171.91, 157.73, 154.35, 
131.07, 128.65, 114.14, 79.39, 65.65, 61.54, 60.40, 60.24, 40.79, 32.01, 28.39, 
23.58, 14.15 ppm, MS: m/z = 381.033 [M] +. 
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d)  N-t-Butoxycarbonyl-O-[3-Br-propyl]-α-methyl tyrosine ethylester  
(Compound 5) 
        A solution of 4 (5.44 g; 16.82 mmol) and 1,3- dibromopropane (136.74 g;  
677.30 mmol) in 100 mL acetone was purged with nitrogen for 15 min. Potassium 
carbonate (22.62 g; 163.69 mmol) was added to the reaction mixture, the mixture 
was then refluxed for 12 h at 75 0C. After the removal of solvents and excessive 
reagents under reduced pressure, the residue was dissolved in chloroform, washed 
with water and dried over anhydrous magnesium sulfate. After filtration and solvent 
evaporation, yellow liquid was purified by a silica gel-packed flash column and 
eluted with hexane/ ethylacetate (2/1) to furnish compound 5 as pale yellow liquid. 
Yield: 4.80 g (7.52 mmol, 64.69 %). MS: m/z = 446.3 [M] +.  
 
e) N1, N4-dioxylyl-1,4,8,11-tetraazabicyclotetradecane (N1,N4-cyclooxamide) 
(Compound 6) 
        N4 cyclam (15.00 g; 74.88 mmol) was dissolved in 150 mL of anhydrous 
ethanol, and then diethyl oxalate (10.94 g; 74.88 mmol) was added. The reaction 
mixture was refluxed 18 h at 75 0C. The solvent was evaporated and the crude 
product was recrystallized in acetone : ethanol to yield white crystals of N1,N4-
dioxylyl-1,4,8,11-1,5,8,12-tetraazabicyclotetradecane (N1,N4-cyclooxamide) 6 . Yield: 
13.64 g (17.31 mmol, 72.00 %). MS: m/z = 255.33 [M]+. 
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f) N-t-Butoxycarbonyl-O-[3-( N1,N4-dioxylyl-1,4,8,11-
tetraazabicyclotetradecane)-propyl]-α-methyl tyrosine ethylester (Compound 
7) 
        Compound 6 (1.00 g; 3.93 mmol) was dissolved in 20 mL of anhydrous DMF 
and treated with a solution of N-t-Butoxycarbonyl-O-[3-Br-propyl]-α-methyl tyrosine 
ethylester 5 (1.74 g; 3.93 mmol) in 40 mL of DMF under nitrogen atmosphere. The 
reaction mixture was heated to reflux for 18 h at 75 0C, and then allowed to cool 
down to room temperature. The solvent was removed in vacuo. The residue was 
dissolved in chloroform (30 mL), washed with water and 1M Na2CO3, (12 mL), and 
then separated for the organic layer. The organic layer was dried with anhydrous 
Magnesium sulfate, filtered and evaporated. The crude compound was purified by a 
silica gel-packed column and eluted with chloroform/ methanol (9/1). Yield: 1.00 g 
(1.63 mmol, 42.00 %). MS: m/z = 618.38 [M]+.  
 
g) O-[3-(N1,N4-dioxylyl-1,4,8,11-tetraazabicyclotetradecane)-propyl]-α-
methyltyrosine ethylester (Compound 8) 
        Compound 7 (0.25 g; 0.40 mmol) was dissolved in dichloromethane (10 mL), 
and then trifloroacetic acid (1.0 mL) was added to it. The solution was stirred over 
night at room temperature, and volatiles were removed in vacuo. The crude 
compound was purified by chromatography over silica gel (chloroform: methanol 9:1) 
as white solid. Yield: 0.20 g (0.39 mmol; 95.69 %). MS: m/z = 517.63 [M]+. 
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h)    O-[3-(1,4,8,11-tetraazabicyclohexadecane)-propyl]-α-methyl tyrosine (N4-
AMT) (Compound 9) 
        10N NaOH (2 mL) was added to a solution of compound 8 (0.20 g; 0.39 mmol), 
which was dissolved in 5 mL of water. The reaction mixture was stirred and refluxed 
over night at 90 0C. The solvent was evaporated under vacuum, giving white solid, 
which was dissolved in 5 mL of water and neutralized with 5N HCl solution to pH = 
7. It was lyophilized and obtained as white solid. The solid was stirred in 25 mL 
anhydrous methanol. After filtration and solvent evaporation, white solid was 
obtained. Yield: 0.20 g (0.46 mmol: 99.0 %). MS: m/z = 436.327 [M]+. 
 
Radiolabeling of N4-AMT with 99mTc 
 N4-AMT (1 mg) was dissolved in 0.2 mL sterile water, followed by adding tin (II) 
chloride (0.1 mL, 1 mg/mL). Required amount of Na99mTcO4 was added to N4-AMT 
solution. Radiochemical purity was determined by radio-HPLC (Waters, Milford, MA), 
eluted with acetonitrile: water (7:3) using a flow rate of 0.5 mL/min. 
  
Determination of the Partition Coefficient 
        To determine the lipophilicity, 20 µL of 99mTc-N4-AMT was added into an equal 
volume mixture of 1-octanol and sterile water in a centrifuge tube. The mixture was 
vortexed at room temperature for 1 min and then centrifuged at 5000 rpm for 5 min. 
From each phase, 0.1 mL of the aliquot was taken out and the radioactivity was 
measured by gamma counter (Cobra Quantum; Packard, MN). The measurement 
was repeated for three times, and care was taken to avoid cross contamination 
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between the phases. The partition coefficient value, expressed as logP, was 
calculated using the following equation: 
LogP = Log (radioactivity in 1-octanol layer / radioactivity in sterile water layer) 
 
   In Vitro Cellular Uptake Studies 
        Rat breast tumor cell line 13762 (American Type Culture Collection, Rockville, 
MD) was selected and the same cell line was used to create the animal model for in 
vivo evaluation. Cells were maintained in Dulbecco’s modified Eagle’s medium and 
nutrient mixture F-12 Ham (DMEM/F12; GIBCO, Grand Island, NY) at 37 oC in a 
humidified atmosphere containing 5% CO2. Cells were plated onto 6-well tissue 
culture plates (2x105 cells/well) and incubated with 99mTc-N4-AMT (0.05 mg/well, 8 
uCi/well), 99mTc-N4 (0.025 mg/well, 8 uCi/well) or 18F-FDG (8 uCi/well) for 0-4 h. 
After incubation, cells were washed with ice-cold PBS twice and detached by 
treating them with 0.5 mL of trypsin for 5 min. Cells were then collected and the 
radioactivity was measured with gamma counter (Cobra Quantum; Packard, MN). 
Data were expressed in mean ±S.D. percent of cellular uptake (%Uptake) in 
triplicate. 
 
In Vitro Competitive Inhibition Study  
        To investigate the transport mechanisms of 99mTc-N4-AMT, the competitive 
inhibition study using L-tyrosine was conducted. The 13762 rat breast tumor cells 
were co-incubated with 99mTc-N4-AMT (8 µg/well, 8 µCi/well) and L-tyrosine for up 
to 1 h. A set of concentrations of L-tyrosine (10-1000x of the N4-AMT concentration) 
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were used. After incubation, cells were washed with ice-cold PBS twice and 
detached by treating them with 0.5 mL of trypsin for 5 min. Cells were then collected 
and the radioactivity was measured by gamma counter. Data were expressed in 
mean ±S.D. percent of cellular uptake (%Uptake) in triplicate. 
 
Blood Clearance 
        All animal work was carried out in the Small Animal Imaging Facility (SAIF) at 
UTMDACC under a protocol approved by Institutional Animal Care and Use 
Committee (IACUC). For blood clearance analysis, three normal female Fischer 344 
rats (150±25 g) (Harlan Sprague-Dawley, Indianapolis, IN) were intravenously 
injected with 30 µCi 99mTc-N4-AMT. Blood samples were drawn through lateral tail 
vein at several time-points from 5 min to 24 h (n=3/rat) by microliter pipettes (10 µL). 
The blood samples were measured for radioactivity by gamma counter, and then 
were calculated as percentage of the injected dose per gram of blood (%ID/g). 
 
In vivo Tissue Distribution Studies 
        Tissue distribution studies of 99mTc-N4-AMT (study I, n=9) and 18F-FDG (study 
II, n=9) were conducted by using normal female Fischer 344 rats (150±25 g, n=18). 
For each compound, the rats were divided into three groups for three time intervals 
(0.5, 2, 4 h for 99mTc-N4-AMT; 0.5, 1, 2 h for 18F-FDG; n=3/time point). The injection 
activity was 25±0.5 µCi/rat intravenously. At each time interval, the rats were 
sacrificed, and the selected tissues were excised, weighed and measured for 
radioactivity by gamma counter. Each sample was calculated as percentage of the 
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injected dose per gram of tissue wet weight (%ID/g). Counts from a diluted sample 
of the original injection were used as reference.  
 
Planar Scintigraphic Imaging Study 
        Female Fischer 344 rats were inoculated subcutaneously with 0.1 mL of breast 
tumor cells 13762 suspension in PBS (105 cells/rat) into the right legs. Planar 
scintigraphic imaging of 99mTc-N4-AMT was performed 12-14 days after inoculation 
when tumors reached approximately 1 cm in diameter. Planar scintigraphic images 
were obtained using M-CAM (Siemens Medical Solutions, Hoffman Estates, IL) 
equipped with a Low Energy High Resolution collimator. Anesthetized breast tumor-
bearing rats were injected intravenously with 99mTc-N4-AMT (0.3 mg/rat, 300 µCi/rat; 
n=3). The images were acquired up to 4 h post-administration of tracers. Computer 
outlined regions of interest (ROIs in counts per pixel) between tumor and muscle 
were used to calculate tumor/muscle (T/M) ratios. Percentage of the injected dose 
(%ID) of tumor was also calculated from the reference standard, which was 1/10 of 
the original injection activity. 
 
In Vivo Uptake Blocking Study 
        To ascertain whether 99mTc-N4-AMT uptake is mediated specifically by LAT, in 
vivo blocking studies using the unlabeled L-Tyrosine as the competitive inhibitor 
was conducted. The same animal model used in the planar scintigraphic imaging 
study was employed. Unlabeled L-Tyrosine (50 mg/kg) dissolved in 0.3 mL saline 
(pH adjusted to 2-3) was administered intravenously to mammary tumor–bearing 
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rats 1 h prior to 99mTc-N4-AMT injection. Planar scintigraphic images were acquired 
up to 4 h, and ROIs of liver, kidneys, tumor, and muscle were used to calculate the 
ratios of liver/muscle, kidney/muscle, and tumor/muscle, respectively. In 
addition, %IDs of liver, kidneys, tumor, and muscle were calculated from the 
reference standard, which was 1/10 of the original injection activity. The results 
were compared with those from the rats injected with 99mTc-N4-AMT alone (control). 
 
Tumor and Inflammation Uptake Comparison In Vivo 
        To investigate whether 99mTc-N4-AMT can differentiate tumor from the 
inflammatory tissue, a rat model bearing both mammary tumor and turpentine oil-
induced inflammation was created. 13762 rat mammary tumor cells (105 cells/0.1 
mL PBS/rat) were inoculated into the right calf muscles of the female Fischer 344 
rats. After the tumors reached to 1 cm in diameter, turpentine oil (0.1 mL/rat) was 
injected into the left calf muscles of the rats to induce inflammation. The 
anesthetized rats (n=3) were injected intravenously with 99mTc-N4-AMT 24 h after 
the turpentine injection. Planar scintigraphic images were acquired up to 4 h, and 
ROIs of tumor, inflammation, and muscle were used to calculate the tumor-to-
muscle ratios (T/Ms), inflammation-to-muscle ratios (I/Ms), and tumor-to-
inflammation ratios (T/Is), respectively. Same animal model was used to evaluate 
18F-FDG. Micro-PET imaging of 18F-FDG was performed using R4 micro-PET 
scanner (Concorde Microsystems, TN). The rats were injected intravenously with 
18F-FDG (500 uCi/rat, n=3), and dynamic PET scans were obtained for 90 min with 
a spatial resolution of 2.2 mm. PET images were reconstructed by using the 
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ordered subset expectation maximization (OSEM) algorithm. T/Ms, I/Ms and T/Is 
ratios were calculated based on the regional radioactivity concentrations (µCi/cm3) 
that were estimated from the average pixels within ROIs drawn around the tumor, 
inflammation or muscle on transverse slices of the reconstructed image sets.  
 
III. Results  
Chemistry and Radiochemistry 
        Precursor N4-AMT was synthesized via an eight-step procedure and the total 
synthesis yield was 14%. The synthetic scheme is shown in Fig.5.1. The structure 
and purity of N4-AMT was confirmed by 1H- and 13C- NMR, mass spectra, and 
HPLC. For N4-AMT, the 1H- and 13C-NMR results were 1H NMR (D2O) δ = 7.21 (d, 
2H, J = 9.00 Hz), 7.00 (d, 2H, J = 9.00 Hz), 4.14 (t, 2H, J = 12.0 Hz), 3.10  (m, 5H), 
2.94 (m, 2H), 2.84 (m, 13H), 1.95 (m, 6H), 1.33 (s, 3H) ppm.13C NMR δ = 180.69, 
163.42, 163.16, 162.88, 162.60, , 157.06, 131.40, 129.19, 117.57, 115.26, 115.10, 
112.93, 66.25,60.73, 53.69, 51.46, 49.88, 49.26, 48.04, 47.84, 46.60, 45.42, 45.07, 
43.94, 24.71, 24.32, 23.62, 22.55 ppm.  
        Precursor N4-AMT was labeled with 99mTc successfully in a high radiochemical 
purity (>96%). For HPLC, the retention time of 99mTc-N4-AMT was 6.899 min. The 
logP of 99mTc-N4-AMT was -1.42±0.169.  
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Figure 5.1. Synthetic scheme of manufacturing of the precursor N4-AMT. 
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In Vitro Cellular Uptake Studies 
        The cellular uptake kinetics of 99mTc-N4-AMT, 99mTc-N4, and 18F-FDG in rat 
breast tumor cells is shown in Fig. 5.2. There was a drastically increased uptake for 
99mTc-N4-AMT at 15-240 min, but not for 99mTc-N4 chelator itself, which suggested 
that 99mTc-N4-AMT can enter and accumulate into tumor cells rapidly and 
specifically. In addition, the %Uptake of 99mTc-N4-AMT was much higher than that 
of 18F-FDG. 
 
 
 
 
Figure 5.2. Time course of 99mTc-N4-AMT, 99mTc-N4 and 18F-FDG uptake in rat breast 
tumor cell line 13762 (0– 240 min). Data are expressed in mean ± S.D. percentage of 
cellular uptake (%Uptake). 
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Competitive Inhibition Study of 99mTc-N4-AMT 
         After incubated with L-tyrosine at 10-1000 times as high as the concentrations 
of N4-AMT, 13762 cells showed a significant decrease in 99mTc-N4-AMT uptake 
only at the 150- and 200-time concentrations (Fig. 5.3). These results indicate that 
99mTc-N4-AMT and L-tyrosine may be transported via the same transporter system 
LAT; however, LAT may not be the only transport route for 99mTc-N4-AMT. 
 
 
 
 
 
Figure 5.3. Competitive inhibition uptake of 99mTc-N4-AMT by L-tyrosine in rat breast 
tumor cell line 13762 up to 1 h. A set of concentrations of L-tyrosine [150X and 200X 
of N4-AMT concentration (8 mg/well)] were used. Data are expressed in mean ± S.D. 
percentage of cellular uptake (%Uptake). 
*P<0.05 compared with the control group. 
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Blood Clearance 
        The blood clearance curve for 99mTc-N4-AMT in normal Fischer 344 rats (n=3) 
is shown in Fig. 5.4. The plasma half-life of the distribution phase (t1/2 α) was 
10.71±0.794 min, while that of the elimination phase (t1/2 β) was 99.32±5.182 min. 
 
 
 
 
 
 
 
 
 
Figure 5.4. Blood clearance (%ID/g) of 99mTc-N4-AMT in normal female Fischer 344 
rats (n=3). The data represent the mean radioactivity expressed as a percentage of 
the injected dose per gram of blood ± S.D.  
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In Vivo Tissue Distribution Studies 
        The tissue distribution results of 99mTc-N4-AMT and 18F-FDG in the normal 
Fischer 344 rats are shown in Tables 5.1 and 5.2, respectively. Low thyroid and 
stomach uptake of 99mTc-N4-AMT was observed, suggesting its high in vivo stability.    
 
Table 5.1. Biodistribution of 99mTc-N4-AMT in normal Fischer 344 female rats. 
 
Each rat received 99mTc-N4-AMT (25 µCi, intravenously). Each value is percent of injected 
dose per gram weight (n= 3)/time interval. Each data represents mean of three 
measurements with standard deviation. 
 
 
 
 
 
%ID/g 30 MIN 120 MIN 240 MIN
blood 0.74 ±0.024 0.28 ±0.010 0.18 ±0.008
heart 0.18 ±0.013 0.08 ±0.006 0.05 ±0.003
lung 0.44 ±0.029 0.22 ±0.004 0.13 ±0.008
thyroid 0.57 ±0.040 0.31 ±0.015 0.24 ±0.012
pancreas 0.18 ±0.006 0.09 ±0.005 0.06 ±0.002
liver 1.40 ±0.077 0.83 ±0.045 0.60 ±0.023
spleen 0.24 ±0.004 0.19 ±0.002 0.18 ±0.011
kidney 5.77 ±0.355 5.32 ±0.180 4.74 ±0.332
stomach 0.50 ±0.029 0.42 ±0.031 0.43 ±0.026
intestine 0.33 ±0.019 0.18 ±0.010 0.13 ±0.006
muscle 0.09 ±0.007 0.03 ±0.002 0.02 ±0.001
bone & joint 0.27 ±0.061 0.11 ±0.006 0.06 ±0.003
brain 0.03 ±0.005 0.01 ±0.001 0.01 ±0.000
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Table 5.2. Biodistribution of 18F-FDG in normal Fischer 344 female rats. 
 
Each rat received 18F-FDG (25 µCi, intravenously). Each value is percent of injected dose 
per gram weight (n =3)/time interval. Each data represents mean of three measurements 
with standard deviation. 
 
 
 
 
 
 
 
 
 
 
%ID/g 30 MIN 60 MIN 120 MIN
blood 0.40 ±0.042 0.13 ±0.006 0.06 ±0.002
heart 1.57 ±0.056 1.38 ±0.126 1.08 ±0.068
lung 0.55 ±0.056 0.42 ±0.024 0.46 ±0.027
thyroid 1.07 ±0.080 1.04 ±0.040 1.05 ±0.069
pancreas 0.26 ±0.028 0.21 ±0.006 0.20 ±0.016
liver 0.40 ±0.048 0.16 ±0.006 0.13 ±0.012
spleen 0.82 ±0.081 0.74 ±0.032 0.86 ±0.071
kidney 0.71 ±0.051 0.37 ±0.012 0.24 ±0.018
stomach 0.61 ±0.078 0.44 ±0.031 0.39 ±0.030
intestine 0.69 ±0.068 0.53 ±0.035 0.52 ±0.025
muscle 0.33 ±0.040 0.34 ±0.027 0.74 ±0.024
bone& joint 0.33 ±0.036 0.44 ±0.065 0.50 ±0.034
brain 2.00 ±0.149 1.99 ±0.046 1.39 ±0.086
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Planar Scintigraphic Imaging Study  
        The representative planar scintigraphic images of 99mTc-N4-AMT at 30 min, 2h, 
and 4 h in breast tumor-bearing rats are shown in Fig. 5.5. Tumors were clearly 
detected by 99mTc-N4-AMT at all time-points. The T/M ratios at 30 min, 2h, and 4 h 
were 5.02, 4.04, and 5.00, respectively. Tumor %IDs at these three time-points 
were 0.76%, 0.51%, and 0.48%, respectively (Fig. 5.5). 
 
 
 
 
 
Figure 5.5. Planar scintigraphy of 99mTc-N4-AMT at 30 – 240 min in rat breast tumor-
bearing rats (T: tumor).  
T/M = 5.02 T/M = 5.00 T/M = 4.04
Tumor %ID: 0.76 Tumor %ID: 0.51 Tumor %ID: 0.48
30 MIN 240 MIN120 MIN
T
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In Vivo Uptake Blocking Study 
        The liver, kidneys, tumor, and muscle %IDs of 99mTc-N4-AMT, as well as the 
ratios of these organs to muscle before and after in vivo blocking by unlabeled L-
Tyrosine were listed in Table 5.3 and 5.4. By using the blocking agent L-Tyrosine, 
99mTc-N4-AMT uptake in liver, kidney, and tumor decreased significantly at all time-
points. Muscle uptake also decreased at the 30 min time-point, which may due to 
the blood flow effect. These results suggest that 99mTc-N4-AMT utilizes the same 
transport system LAT as L-Tyrosine does in vivo.  
 
 
Table 5.3. Percentage of injected dose (%ID) of selected organs before and after in vivo 
blocking of 99mTc-N4-AMT by unlabeled L-Tyrosine in mammary tumor-bearing rats. Red 
font indicates the decreased %ID when compared to the corresponding control group. 
Blue shading indicates P<0.05 when compared to the corresponding control group 
(n=3/group/time interval). 
 
 
 
 
%ID
30 min 2 hr 4hr
Control Block Decrease Control Block Decrease Control Block Decrease
Liver 7.63±0.47 6.31±0.18 17.30% 5.12±0.24 4.40±0.33 14.06% 4.49±0.32 3.39±0.09 24.50%
Kidney 5.81±0.35 4.62±0.45 20.48% 4.26±0.25 3.32±0.14 22.07% 4.35±0.33 3.05±0.16 29.89%
Tumor 2.71±0.22 1.63±0.05 39.85% 0.84±0.05 0.43±0.04 48.81% 0.55±0.04 0.37±0.02 32.73%
Muscle 0.58±0.11 0.42±0.04 27.59% 0.11±0.02 0.11±0.04 0.00% 0.077±0.005 0.082±0.012 -6.49%
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Table 5.4. Selected organ to muscle ratios before and after in vivo blocking of 99mTc-N4-
AMT by unlabeled L-Tyrosine in mammary tumor-bearing rats. Red font indicates the 
decreased %ID when compared to the corresponding control group. Blue shading 
indicates P<0.05 when compared to the corresponding control group (n=3/group/time 
interval). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ratio
30 min 2 hr 4hr
Control Block Decrease Control Block Decrease Control Block Decrease
Liver/Muscle 13.1±0.5 15.1±0.4 -15.27% 45.6±1.5 41.1±2.1 9.87% 58.0±2.3 41.1±2.2 29.14%
Kidney/Muscle 9.96±0.49 11.0±0.53 -10.24% 38.0±1.3 31.1±2.4 18.16% 56.1±1.3 37.0±0.3 34.05%
Tumor/Muscle 4.65±0.28 3.89±0.1 16.34% 7.48±0.34 4.03±0.16 46.12% 7.12±0.35 4.55±0.27 36.10%
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Tumor and Inflammation Uptake Comparison In Vivo 
        The representative planar scintigraphic images of 99mTc-N4-AMT, as well as 
the micro-PET images of 18F-FDG in breast tumor and inflammation-bearing rats 
are shown in Fig. 5.6 and Fig. 5.7, respectively. The T/M of 99mTc-N4-AMT at each 
time-point was much higher than I/M. Although T/I at all time-points were above 1, 
which indicated that tumor had higher uptake than the inflammation site, the ratios 
were similar to those of 18F-FDG. Therefore, these results suggested that 99mTc-N4-
AMT was not superior to 18F-FDG in differentiating tumor from inflammation. 
 
 
 
 
Figure 5.6. Planar scintigraphic images of 99mTc-N4-AMT at 30 – 240 min in rat breast 
tumor and inflammation-bearing rats (T: tumor, I: inflammation). The tumor-to-muscle 
ratios (T/Ms), inflammation-to-muscle ratios (I/Ms), and tumor-to-inflammation ratios 
(T/Is) are listed below the figure. 
30 min 2 hr 4 hr
T/M 4.49 5.59 5.15
I/M 2.95 3.47 2.71
T/I 1.52 1.61 1.90
30 MIN 240 MIN120 MIN
T
I
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Figure 5.7. microPET images of 18F-FDG at 30 – 90 min in rat breast tumor and 
inflammation-bearing rats (T: tumor, I: inflammation). The tumor-to-muscle ratios 
(T/Ms), inflammation-to-muscle ratios (I/Ms), and tumor-to-inflammation ratios (T/Is) 
are listed below the figure. 
Transverse Saggital Axial
T I
T I
T I
30 min
60 min
90 min
30 min 60 min 90 min
T/M 5.88 7.54 4.90
I/M 3.43 3.77 2.72
T/I 1.71 1.99 1.80
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IV. Discussion  
        The present study investigated the imaging capability of 99mTc-N4-AMT in 
breast tumor models in vitro and in vivo. For chemical synthesis, the precursor N4-
AMT was synthesized via an eight-step procedure (Fig. 5.1). Commercially 
available α-methyl tyrosine 1 was converted into corresponding acid chloride, then 
to ethyl ester by reacting with thionyl chloride in ethanol. The amine in α-methyl 
tyrosine ethyl ester 2 was protected as its Boc-derivative N-t-butoxycarbonyl-α-
methyl tyrosine ethylester 3 with triethylamine and di-t-butyldicarbonate in DMF. 
The chain at the -OH group was extended when compound 3 was treated with 1, 3-
dibromopropane and obtained as N-t-butoxycarbonyl-O-[3-bromopropyl]-α-methyl 
tyrosine ethylester 4. Acylation of 1,4,8,11- tetraazacyclo-tetradecane (N4 cyclam)  
with diethyloxalate led to N1,N4-dioxalyl 1,4,8,11- tetraazacyclotetradecane (N1,N4-
cyclamoxamide) 5. Under SN2 condition 4 and 5 were efficiently converted to 
alkylated compound N-t-butoxycarbonyl-O-[3-(N1,N4-dioxalyl-1,4,8,11-
tetraazacyclotetradecane)-propyl]-α-methyl tyrosine ethylester 6. Exposure of 6 to 
trifloroacetic acid in CH2Cl2 caused qualitative de-t-butoxycarboxylation to yield O-
[3-(N1, N4-dioxalyl 1,4,8,11-tetraazacyclotetradecane)-propyl]-α-methyl tyrosine 
ethylester 7. 10 N NaOH in water at 75 0C promoted the hydrolysis of ester to acid 
and a simultaneous deoxalation of 7 to yield the final compound O-[3-(1,4,8,11-
tetraazacyclotetradecan)-propyl]-α-methyl tyrosine (N4-AMT) 8. The total synthesis 
yield was 14%, which can be adapted to industrial manufacturing. The structure and 
purity of the compounds at each step were validated by 1H- and 13C- NMR, mass 
spectra, and HPLC. Precursor N4-AMT could be labeled with 99mTc successfully in 
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a high radiochemical purity (>96%). Given that 99mTc-N4-AMT is a kit-product and 
labeled without any further purification, the radiochemical yield was assumed to be 
identical to its radiochemical purity.  
        In cellular uptake study, 99mTc-N4-AMT was taken up rapidly by rat mammary 
tumor cells, and the %Uptake of 99mTc-N4-AMT was significantly higher than that of 
the chelator 99mTc-N4, suggesting its high specificity in tumor uptake. Besides, 
99mTc-N4-AMT has much more uptake than 18F-FDG in this in vitro breast cancer 
model. In competitive inhibition study, 99mTc-N4-AMT uptake could be significantly 
inhibited by L-tyrosine only at the 150- and 200-time concentrations, which indicates 
that 99mTc-N4-AMT and L-tyrosine may be transported via the same transporter 
system LAT; however, LAT may not be the only transport route for 99mTc-N4-AMT. 
To further investigate other transport routes, different types of amino acid 
transporter inhibitors need to be tested in order to block the 99mTc-N4-AMT uptake 
in this breast cancer cell line in future.  
         For in vivo evaluation, 99mTc-N4-AMT had a relatively fast blood clearance in 
normal Fischer 344 rats (Fig. 5.4). Biodistribution study showed that 99mTc-N4-AMT 
had a favorable distribution pattern in normal rats (Table 5.1). The two major organs 
for 99mTc-N4-AMT metabolism are kidneys and liver. In planar imaging studies 
shown in Fig. 5.5, tumors were clearly detected by 99mTc-N4-AMT at all time-points. 
Although its T/Ms were relatively high, the tumor %IDs were lower than that of other 
99mTc-labeled tyrosine derivatives we developed previously. To ascertain whether 
99mTc-N4-AMT uptake is mediated specifically by LAT, we then conducted the in 
vivo uptake blocking studies using the unlabeled L-Tyrosine as the competitive 
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inhibitor (Table 5.3 and 5.4). Upon blocking, 99mTc-N4-AMT uptake in liver, kidney, 
and tumor decreased significantly at all time-points. Although muscle uptake also 
decreased at the 30 min time-point, the decreasing rate was not statistically 
significant and it may due to the blood flow effect. These results suggest that 99mTc-
N4-AMT may utilize the same transport system LAT as L-Tyrosine does in vivo. To 
test whether 99mTc-N4-AMT can distinguish tumor from inflammatory tissues, we 
have established a rat model bearing both mammary tumor and turpentine oil-
induced inflammation. Although T/Is at all time-points were above 1, which indicated 
that tumor had higher uptake than the inflammation site, the ratios were similar to 
those of 18F-FDG. Nevertheless, since the uptake in inflammatory tissue was 
caused by blood flow effect, T/I ratios of 99mTc-N4-AMT increased by time. 
Therefore, 99mTc-N4-AMT may be able to distinguish tumor from inflammation in a 
later time-point by taking the advantage of using the long half-life radioisotope 99mTc. 
In addition, we may need to test 99mTc-N4-AMT in another animal model using 
radiation to induce inflammation in future so it can more similarly mimic the patients 
undergoing radiation therapy.    
        In conclusion, efficient synthesis of N4-AMT was achieved.  In vitro cellular 
uptake and in vivo imaging findings collectively suggest that 99mTc-N4-AMT is a 
potential radiotracer for breast cancer imaging. In compliance with the chelating 
capability of N4, N4-AMT could be labeled with positron emitting radionuclides such 
as Gallium-68 or with short-ranged beta emitters for internal radiotherapeutic 
purposes hereafter. 
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CHAPTER 6   Overview: comparison of 99mTc-labeled Tyrosine-
based radiotracers in breast cancer imaging 
        In this dissertation, four 99mTc-labeled tyrosine derivatives have been 
synthesized and evaluated in vitro and in vivo for their imaging potential in breast 
cancer models (Fig. 6.1). The detailed methods and results of the synthesis and 
evaluation of each radiotracer have already been stated in Chapter 2-5. The studies 
designed for each specific aim were listed in Table 6.1. Here, we will compare these 
four radiotracers and score them as 1 to 4. Score 1 indicates the best compound 
and score 4 is the worst compound for each study. Therefore, the compound with 
the least score will be the best radiotracer for imaging breast cancer modeled here 
overall. 
 
   
 
 
Figure 6.1. Proposed structures of four tyrosine-based precursors. 
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Table 6.1. The studies designed to synthesize and evaluate four radiotracers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EC-AMT EC-Tyrosine N4-AMT N4-Tyrosine
SA1
Precursor Synthesis
99mTc Labeling
Partition Coefficient
SA2
Uptake Kinetics
Competitive Inhibition using L-Tyrosine
SA3
Blood Clearance
Biodistribution
Planar Imaging  (breast cancer model)
Planar Imaging (in vivo blocking)
Planar Imaging (breast cancer vs. inflammation model)
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I. Specific Aim 1 
        Table 6.2 summarized the chemical synthesis of four precursors. Since N-t-
Butoxycarbonyl-L-tyrosine methyl ester, the starting material of the protected Br-
tyrosine compound was commercially available; the required synthetic steps of EC-
Tyrosine and N4-Tyrosine were fewer than those of their α-methyl derivatives, 
hence, the overall synthetic yields were much higher than EC-AMT and N4-AMT, 
respectively. As shown in Table 6.2, the best compound with fewest synthesis steps 
and highest synthetic yield was EC-Tyrosine. Nevertheless, the other three 
compounds also had acceptable synthetic yield. 
        When label the precursors with 99mTc, the radiochemical purity of four 
compounds was all above 95%. Since they are kit-products and labeled without any 
further purification, the radiochemical yield is assumed to be identical to their 
radiochemical purity. However, EC seemed to have better chelation ability with 
99mTc than N4 because EC-AMT and EC-Tyrosine can be labeled with 99mTc using 
lesser physical amount than their N4 counterpart.  
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Table 6.2. Summary of the chemical synthesis of four precursors. 
 
 
        The partition coefficient values (logPs) of four radiotracers were listed in Table 
6.3. Since all four compounds are small molecule, the compound with higher 
lipophilicity is preferred because they will have better chance to be slowly washed 
out from body than the compound with lower lipophillicity. Based on the results, 
99mTc-EC-AMT had highest lipophilicity and therefore was the best compound 
among these four radiotracers. As expected, the logPs of tyrosine-based 
radiotracers were lower than those of their α-methyl derivatives. As we know, the 
lower logP indicates the lower lipophilicity of the compound. The result verified our 
hypothesis that the lipophilicity of tyrosine-based radiotracer could be increased by 
adding a methyl group on its α-carbon. In addition, we found that EC-chelated 
radiotracers had higher lipophilicity than their N4 counterpart. When we compared 
lipophilicity of chelator EC and N4 using ChemBioDraw Ultra 12.0 software 
(CambridgeSoft Corporation, Cambridge, MA), the same result was presented. The 
logP of precursor EC was -1.05 whereas that of N4 was -1.3. Although it contains 
Synthesis Steps Overall Yield
EC-AMT 5 23%
EC-Tyrosine 3 80%
N4-AMT 8 14%
N4-Tyrosine 5 38%
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two hydrophilic carboxylic groups, the higher logP of EC may be due to its two 
lipophilic thiol groups.  
 
Table 6.3. The partition coefficient value (logP) of four radiotracers at pH=5-6 (n=6). 
 
 
        Table 6.4 summarizes the conclusion for Specific Aim 1. From the chemical 
point of view, EC-chelated compounds tied for the first place, which suggests that 
both EC-chelated compounds have more favorable chemical characteristics than 
N4-chelated compounds. 
 
Table 6.4. Conclusion of Specific Aim 1. Score 1 indicates the best compound, and score 
4 indicates the worst compound. 
 
 
99mTc-EC-AMT 99mTc-EC-Tyrosine 99mTc-N4-AMT 99mTc-N4-Tyrosine
LogP -1.14±0.072 -2.02±0.168 -1.42±0.169 -2.83±0.082
EC-AMT EC-Tyrosine N4-AMT N4-Tyrosine
SA1
Precursor Synthesis 3 1 4 2
99mTc Labeling 1 1 2 2
Partition Coefficient 1 3 2 4
Conclusions 1 1 2 2
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II. Specific Aim 2 
        Specific Aim 2 was to investigate the uptake kinetics and transport 
mechanisms of 99mTc-labeled tyrosine/AMT-based radiotracer in rat mammary 
tumor cell line 13762. This is a well-documented cell line for established in vivo rat 
mammary tumor model, as well as for the rat model carrying both tumor and 
inflammation employed in differential diagnostic studies. In addition, since we were 
evaluating the compounds using planar scintigraphic imaging, rat model would 
provide better imaging quality than mouse model in terms of resolution. 
        Fig. 6.2 demonstrates the cellular uptake kinetics of all four 99mTc-labeled 
tyrosine-based compounds in comparison with that of 18F-FDG. All four radiotracers 
were taken up rapidly by rat mammary tumor cells and had much higher %Uptake 
than that of 18F-FDG, suggesting their higher imaging potentials than 18F-FDG in 
vitro.  
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        In competitive inhibition study using the same cell line, the uptake of both 
99mTc-EC-AMT and 99mTc-EC-Tyrosine could be blocked by L-Tyrosine from 10-time 
concentration, whereas that of 99mTc-N4-AMT could only be blocked at 150- and 
200-time concentrations of precursor. For 99mTc-N4-Tyrosine, the uptake could not 
be inhibited at any concentration and the uptake even increased by adding 
unlabeled L-Tyrosine. Taken together, these findings suggest that 99mTc-EC-labeled 
compounds most likely share the same transport mechanism as L-Tyrsoine, which 
is predominantly transported via LAT system. For 99mTc-N4-labeled compounds, 
they most likely do not use LAT as a major transport system. 
 
 
Figure 6.2. Time course of 99mTc-labeled four radiotracers and 18F-FDG uptake in rat 
breast tumor cell line 13762 (0– 240 min). Data are expressed in mean ± S.D. 
percentage of cellular uptake (%Uptake). 
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        Table 6.5 summarizes the conclusion for Specific Aim 2. When evaluating 
these four compounds in breast cancer cell line, 99mTc-EC-AMT shows the most 
favorable characteristics in vitro.  
 
Table 6.5. Conclusion of Specific Aim 2. Score 1 indicates the best compound, and score 
4 indicates the worst compound. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EC-AMT EC-Tyrosine N4-AMT N4-Tyrosine
SA2
Uptake Kinetics 1 3 2 4
Competitive Inhibition using L-Tyrosine 1 1 2 3
Conclusions 1 2 2 3
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III. Specific Aim 3 
        Specific Aim 3 was to assess the kinetics of 99mTc-labeled tyrosine/AMT-based 
radiotracer accumulation in tumor and inflammation tissues in mammary tumor-
bearing rat model. The rat tumor model was created using the same rat mammary 
tumor cell line as in the in vitro evaluation. 
        All four radiotracers had relatively rapid blood clearance in normal Fischer 344 
rats (Fig. 6.3). Among them, 99mTc-N4-Tyrosine had the fastest clearance for both 
distribution phase (T1/2 α=9.31±0.759 min) and excretion phase (T1/2 β=90.14±1.901 
min), whereas 99mTc-EC-Tyrosine had the slowest but still acceptable clearance for 
both distribution phase (T1/2 α=13.68±1.067 min) and excretion phase (T1/2 
β=117.51±5.727 min). 
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Figure 6.3. Blood clearance (%ID/g) of four 99mTc-labeled radiotracers in normal 
female Fischer 344 rats up to 240 min (n=3). The data represent the mean 
radioactivity expressed as a percentage of the injected dose per gram of blood ± S.D.  
 
0.000
0.500
1.000
1.500
2.000
2.500
3.000
3.500
4.000
4.500
0 30 60 90 120 150 180 210 240
%
ID
/g
Time (min)
99mTc-EC-AMT
99mTc-EC-Tyrosine
99mTc-N4-AMT
99mTc-N4-Tyrosine
Time (min) 99mTc-EC-AMT 99mTc-EC-Tyrosine 99mTc-N4-AMT 99mTc-N4-Tyrosine
T1/2 α 9.41±0.202 13.68±1.067 10.71±0.794 9.31±0.759
T1/2   β 98.75±5.377 117.51±5.727 99.32±5.182 90.14±1.901
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          For biodistribution study, all four radiotracers had high in vivo stability in 
normal Fischer 344 rats. High kidney uptakes of all compounds were observed up 
to 4 hr, indicating that the kidneys are the major organ for metabolism and excretion 
of these compounds. The high kidney uptake, nevertheless, could be blocked by 
intravenously administration of unlabeled L-Tyrosine, which suggested that the four 
radiotracers may utilize the same metabolism and excretion route as L-Tyrosine 
does in rat kidneys.    
        In planar imaging studies, mammary tumors were clearly detected by all 
radiotracers up to 4 hr. 99mTc-EC-AMT had the highest T/M ratios, and due to the 
washout of non-specific uptake, the T/M ratios increased by time. Therefore, 99mTc-
EC-AMT is the best compound for imaging mammary tumor in this rat model. The 
T/M ratios of the other three compounds also ranged from 4 to 5, and were 
promising for tumor imaging, however, 99mTc-N4-AMT may have the least potential 
because its low tumor %ID.   
        To ascertain whether the radiotracers uptakes are mediated specifically by 
amino acid transporter system LAT, we conducted the in vivo uptake blocking 
studies using the unlabeled L-Tyrosine as the competitive inhibitor. Except for 
99mTc-N4-Tyrosine, all other three compounds were confirmed to transport via the 
same LAT system as unlabeled L-Tyrosine does. These findings were consistent 
with the in vitro competitive inhibition results. Since the lipophilicity of 99mTc-N4-
Tyrosine was much lower in comparison with the other three compounds, it was 
possible that N4-Tyrosine was under some conformational changes when be 
labeled with 99mTc. Thus, 99mTc-N4-Tyrosine could not be recognized as an amino 
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acid and then to be transported via LAT system. In order to test this hypothesis, we 
need to synthesize the cold reference standard Re-N4-Tyrosine and study its 
crystalline structure to confirm the binding site of rhenium in the future. 
        To test whether the radiotracers could differentiate breast tumor from 
inflammation, we performed tumor and inflammation uptake comparison study in 
vivo. All radiotracers other than 99mTc-EC-AMT had tumor-to-inflammation (T/I) ratio 
above 1, which indicated that tumor had higher radiotracer uptake than 
inflammatory site. However, when compared with the clinical gold standard 18F-FDG, 
only 99mTc-EC-Tyrosine had better T/Is up to 4 hr. Therefore, we conclude that 
99mTc-EC-Tyrosine is the most suitable compound for in differentiating tumor from 
inflammatory sites.   
        Table 6.6 summarizes the conclusion for Specific Aim 3. When evaluating 
these four compounds in vivo, 99mTc-EC-AMT shows the most favorable 
characteristics overall. However, 99mTc-EC-Tyrosine will be the most suitable 
candidate for differential diagnosis of tumor from inflammation.     
 
Table 6.6. Conclusion of Specific Aim 3. Score 1 indicates the best compound, and score 
4 indicates the worst compound. 
 
EC-AMT EC-Tyrosine N4-AMT N4-Tyrosine
SA3
Blood Clearance 2 4 3 1
Biodistribution 2 3 1 3
Planar Imaging  (breast cancer model) 1 2 4 2
Planar Imaging (in vivo blocking) 1 2 1 3
Planar Imaging (breast cancer vs. inflammation model) 4 1 2 3
Conclusions 1 3 2 3 
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IV. Conclusions and Future Directions 
        In conclusion, four tyrosine and AMT-based precursors have been successfully 
synthesized and radiolabeled with 99mTc. Table 6.7 summarizes the final 
conclusions of the whole project. Base on the score system, we conclude that 
99mTc-EC-AMT is the most suitable radiotracer for breast cancer imaging overall, 
however, 99mTc-EC-Tyrosine will be a more preferential choice for differential 
diagnosis of tumor from inflammation. 
        In the future, we will use 99mTc-EC-Tyrosine to evaluate the treatment 
response of anti-cancer drugs or radiation therapy since it showed impressive 
capability to distinguish the actual tumors from treatment-induced inflammation. In 
addition, we will label these four precursors with gallium-68 and investigate their 
imaging potentials in breast cancer imaging using PET or PET/CT. Furthermore, we 
would like to label precursor EC-AMT with therapeutic radioisotope rhenium-188 or 
yttrium-90 for cancer treatment given its high tumor accumulation (tumor %ID) and 
T/M ratios.  
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Table 6.7. Final conclusions of the dissertation. Score 1 indicates the best compound, 
and score 4 indicates the worst compound. 
 
 
 
 
 
 
 
 
 
 
 
 
EC-AMT EC-Tyrosine N4-AMT N4-Tyrosine
SA1
Precursor Synthesis 3 1 4 2
99mTc Labeling 1 1 2 2
Partition Coefficient 1 3 2 4
SA2
Uptake Kinetics 1 3 2 4
Competitive Inhibition using L-Tyrosine 1 1 2 3
SA3
Blood Clearance 2 4 3 1
Biodistribution 2 3 1 3
Planar Imaging  (breast cancer model) 1 2 4 2
Planar Imaging (in vivo blocking) 1 2 1 3
Planar Imaging (breast cancer vs. inflammation model) 4 1 2 3
Conclusions 1 2 3 4
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